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Abstract 
 
Background: Observational studies have suggested a possible link between vitamin A 
and cardiovascular disease mortality risk. However, randomized supplementation trials have 
failed to show improvement in survival. There is insufficient evidence on the effects of low 
and elevated subclinical vitamin A status on mortality risk in populations that show no signs 
of vitamin A deficiency or toxicity.  
Method: We evaluated all-cause, CVD-related and non-CVD-related mortality risk 
associated with continuous data, quartiles and deciles of plasma retinol concentration, in 
3842 patients with established CVD of the Bergen Coronary Angiography Cohort and the 
Western Norway B Vitamin Intervention Trial. 
Results: Over the mean seven years and three months of follow-up, there were 280 
deaths, including 149 from CVD and 131 from non-CVD. Patients with high levels of plasma 
retinol concentration had a higher risk of total and non-CVD mortality than patients with 
plasma retinol concentration in the ‘middle range’. High plasma retinol levels were also 
associated with increased risk of CVD-related mortality, adjustment for confounders did not 
change the assumption substantially, but significance was lost. Patients with low plasma 
retinol also had a higher mortality risk, but the association did not achieve significance.  
Conclusion: Our findings suggest that low or high plasma retinol levels does not predict 
CVD-related mortality singularly but rather predicts increased all-cause mortality.  
Impact: The results suggest that further study of association is needed, and for more 
tailored intervention studies based on participants serum retinol levels, that if possible are 
adjusted for markers of systemic inflammatory response.   
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Abstrakt 
Bakgrunn: Observasjonsstudier har indikert en mulig sammenheng mellom vitamin A og 
økt risiko for hjerte- og karsykdomsrelatert dødelighet. Randomiserte intervensjonsstudier 
har derimot ikke lykkes i å redusere risiko for hjerte- og karsykdomsrelatert død. Det 
mangler evidens for mulig effekt av høye og lave sub-kliniske nivåer av vitamin A på 
dødelighet i populasjoner som ikke viser tegn til vitamin A-mangel eller -toksisitet. 
Metode: Vi har evaluert total dødelighet, hjerte- og karsykdomsrelatert og ikke hjerte- 
og karsykdomsrelatert dødelighetsrisiko opp mot kontinuerlige nivå, kvartiler og desiler av 
plasma retinol, hos 3842 pasienter med etablert hjerte- og karsykdom fra BECAC og WENBIT.   
Resultat: Pasientene ble fulgt opp over syv år og tre måneder, hvor 280 døde, 149 av 
hjerte- og karsykdoms relaterte årsaker og 131 av ikke hjerte- og karsykdoms relaterte 
årsaker. Pasienter med høye plasma retinol-verdier hadde høyere total dødelighet og ikke 
hjerte- og karsykdoms-relatert dødelighet sammenliknet med pasienter med middel verdier 
av plasma retinol. Høye plasma retinol-verdier var også assosiert med økt hjerte- og 
karsykdoms-relatert dødelighet, justering for kofaktorer endret ikke assosiasjonens 
størrelse, men endringen i dødelighet var ikke lenger signifikant. Pasienter med lave plasma 
retinol-verdier hadde også økt dødelighetsrisiko, men assosiasjonen var aldri signifikant. 
Konklusjon: Resultatene indikerer at lave og høye plasma retinol-verdier ikke eksklusivt 
forklarer den økte risikoen for hjerte- og karsykdoms-relatert dødelighet, men heller økt 
risiko for total dødelighet.  
Relevans: Videre utforsking av assosiasjonene analysert i dette studiet er nødvendig. I 
tillegg kan det virke hensiktsmessig med justering for serum retinol-verdier og markører for 
inflammatorisk respons i fremtidige intervensjonsstudier.   
  
  
10  
 
1 Introduction 
1.1 Non-communicable disease 
Non-communicable diseases (NCD) are a group of diseases that are defined by the 
World Health Organization (WHO) as; “a medical condition or disease that is by definition non-
infectious and non-transmissible among people” [1]. NCD’s are the leading cause of death 
globally, responsible for 36 million of the 57 million deaths that occurred globally in 2008. Of 
the 36 million deaths, the majority were due to cardiovascular disease (CVD), cancer, 
diabetes and chronic lung disease. Despite the rapid growth of these diseases globally and 
especially in low- and middle-income populations and countries, a reduction in mortality is 
seen in other parts of the world. Moreover, the WHO predicts that the number of NCD related 
deaths are going to increase globally by 15% from 2010 to 2020 [2, 3]. 
1.2 Cardiovascular disease 
As for individual disease prevalence, CVD is the leading cause NCDs and the leading 
cause of death globally. CVDs are diseases affecting the heart and blood vessels. The 
underlying pathology is atherosclerosis, which develops over several years and is usually 
advanced by the time symptoms occur [4]. 
1.2.1 Definition 
WHO defines CVD as; “any disease plaguing the heart and its associated blood 
vessels. These include a variety of diseases including coronary heart disease, stroke, and 
peripheral vascular diseases” [5]. WHO divides cardiovascular diseases by their origin, into 
those due to atherosclerotic origin and those not related to atherosclerosis. The most 
prevalent diseases related to atherosclerosis are ischemic heart disease or coronary heart 
disease (e.g. heart attack), cerebrovascular disease (e.g. stroke) and diseases of the aorta 
and arteries, including hypertension and peripheral vascular disease. The CVDs not directly 
related to atherosclerosis are congenital heart disease, rheumatic heart disease, 
cardiomyopathies and cardiac arrhythmias [4, 5].  
1.2.2 Prevalence 
1.2.2.1 Globally 
WHO states in their report from 2010 that CVD is the leading cause of death globally. 
17.3 million People died from CVDs in 2008, this is 30% of the total 57 million deaths 
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globally. Of the 17,3 million people who died from CVDs in 2008 heart attacks caused  7.3 
million deaths and stroke 6.2 million deaths [3, 4].   
1.2.2.2 In Norway 
Similar rates of CVD death were observed in Norway 2012. Of the 41,913 deaths that 
occurred in Norway 2012, 13,010 (31%) were caused by CVDs according to data published 
November 2013 by Statistics Norway [6]. The report by Statistics Norway also states that the 
mortality rate per inhabitant continues to drop as it has done since 1988. So despite the 
decrease in mortality rate per inhabitant CVDs still  causes 30 percent of annual deaths 
nationally [6, 7]. 
Side 10 PCD 
1.2.3 Risk factors 
Risk factors for CVD and especially the atherosclerotic related conditions are known 
as major contributors to global morbidity and mortality, not only for their promotion of CVD. 
The risk factors acknowledged by the WHO are divided into groups by origin and listed below 
[4].  
1.2.3.1 Behavioral risk factors 
1. Tobacco use 
2. Physical inactivity 
3. Unhealthy diet (rich in salts, fat and calories) 
4. Harmful use of alcohol 
1.2.3.2 Metabolic risk factors 
5. Raised blood pressure (hypertension) 
6. Raised blood sugar (diabetes) 
7. Raised blood lipids (e.g. cholesterol) 
8. Overweight and obesity 
1.2.3.3 Other risk factors 
9. Poverty and low educational status 
10. Advancing age 
11. Gender 
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12. Inherited (genetic) disposition 
13. Physiological factors (e.g. stress, depression) 
14. Other risk factors (e.g. excess homocysteine) 
1.2.4 Etiology 
The main pathological process that leads to heart attacks and stroke is atherosclerosis. 
The process of atherosclerotic development is the result of numerous risk factors and may 
start as early as during childhood and adolescence. Atherosclerosis is an inflammatory 
process affecting the elastic and muscular layers of medium and large-sized arteries 
throughout the cardiovascular system [4, 8].  
As the endothelium of these blood vessels are exposed to above tolerated levels of low-
density lipoprotein (LDL) cholesterol, and certain other substances, such as free radicals, 
damage may occur. The presence of LDL cholesterol and free radicals results in the 
endothelium becoming permeable to lymphocytes and monocytes. The lymphocytes and 
monocytes then migrate into the deep layers of the wall of the blood vessel. A series of 
reactions occur, attracting LDL cholesterol particles to the site. The monocytes engulf the 
LDL cholesterol particles and then transform into macrophages (foam cells). With the 
accumulation of foam cells, smooth muscle cells (SMC) migrate to the site from deeper 
layers of the vessel wall (the media), leading to the formation of a fibrous cap of SMC and 
collagen. At the same time, the macrophages involved in the original reaction begin to die, 
resulting in the formation of a necrotic core covered by the fibrous cap. These lesions 
(atheromatous plaques) enlarge as cells and lipids accumulate [8].  
As the accumulation continues, the plaque begins to bulge into the vessel lumen, leading 
to a thinning of the fibrous cap accompanied by cracking of the endothelial surface of the 
plaque, which may finally rupture. With the rupture of the plaque, lipid fragments and 
cellular debris enter the vessel lumen (bloodstream). Thrombotic agents on the endothelial 
surface react with the intruding particles, resulting in the formation of a thrombus. If the 
thrombus is large enough, and the blood vessel or cerebral blood vessel is blocked,  the 
result may be a heart attack or stroke [4]. 
Holligan et al. states that increased plasma low density lipoproteins cholesterols (LDL-C) 
increase the stress on dysfunctional areas of the arterial wall, this because the small particles 
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of LDL-C are more susceptible to modification. LDL modification, also known as oxidation of 
LDL particles, contributes to the activation and accumulation of macrophages and other 
monocytes. Both intrinsic factors such as antioxidant content, fatty acid composition, and 
particle size increase the susceptibility of LDL to oxidation and movement through the 
injured endothelial layer. Extrinsic factors like surrounding pH, local antioxidant 
concentration, and transitional metal availability contributes to efficiency of oxidation. 
Oxidized LDL (OxLDL) is atherogenic and is a direct and indirect-chemoattractant for 
circulating monocytes [8].   
Indirect-chemoattractance is a result of OxLDL mediated release of monocyte 
chemoattractant protein-1 from the endothelial cells in to the lumen. OxLDL inhibits the 
movement of local macrophages and in turn promotes the differentiation of monocytes into 
tissue macrophages via the release of macrophage colony-stimulating factor from the 
endothelial cells. The indirect-chemoattractance process also attracts T-lymphocytes. These 
actions facilitate the loss of endothelial integrity [8].   
Most of the chronic inflammatory diseases are characterized by overproduction of 
cytokines, chematokines, eicosanoids, and matrix metalloproteinase. These substrates or 
mediators amplify the inflammation by attracting inflammatory cells to the site and thereby 
contributing to the tissue destruction. Many of these mediators are positively regulated 
through nuclear factor kappa-light-chain-enhancer of activated B cells and some are 
negatively regulated through peroxisome proliferator-activated receptor (PPAR) and liver x 
receptors [8]. The continued cycle of tissue injury, healing, and repair is the result of 
cytokines, chematokines and growth factor release. The inflammatory cells and the resident 
tissue cells produce this release. The process eventually results in the tissue remodeling seen 
in the vascular lumen during atherosclerosis [9].  
1.2.4.1 Heart Attack 
A heart attack or myocardial infraction happens when the blood flow to the heart 
muscle or parts of the heart muscle is cut-off. The restriction of blood supply is often the 
result of a thrombus in a supplying blood vessel. The reduced blood supply starves the heart 
muscle of oxygen and nutrients, causing injury, which in turn can result in a heart attack, 
often referred to as an acute myocardial infraction (AMI). Blockages can cause mild 
  
14  
 
reduction in blood flow. This may lead to reduced blood supply to the heart (ischemia) and 
thus chest pain (angina) [4]. 
1.2.4.2 Stroke 
The pathophysiology of strokes is more diverse than that of a heart attack. Ischemic 
strokes are strokes happening due to thrombus formation in atherosclerotic cerebral blood 
vessels, or small vessel disease in the brain linked to vascular risk factors. Stroke may also 
happen because of a haemorrhage (bleeding) event due to the rupture of a blood vessel 
caused by the presence of an aneurysm, for example, or due to damage from uncontrolled 
high blood pressure or atherosclerosis (haemorrhage stroke). Additionally, traveling blood 
clots can cause a stroke if they end up blocking a blood vessel in the brain. For instance if a 
person has an irregular heartbeat, blood clots may form in the heart and travel through the 
blood vessels to the brain [4].  
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1.3 Epidemiological studies 
Epidemiology is the science of studying patterns, causes, health, disease and death in a 
population. Epidemiological studies investigate association and causality between exposure 
and outcome in populations. The exposure can be a risk factor, a prognostic factor, a 
diagnostic test, a treatment, or as in this study plasma retinol (vitamin A). While outcome is 
often measured in prevalence of death or disease. Results of epidemiological studies is 
usually presented as; risk, rate, prevalence, odds, or frequency of outcome, and comparing 
outcomes between groups of participants divided according to exposure will yield relevant 
frequency measures [10].  
There are several different ways of performing epidemiological studies. This study 
will follow a secondary, quantitative, observational, retrospective, cohort design. The 
dataset used in this study has been assembled prior to the start of this project by another 
project and consists of quantitative data in form of anthropometric, biochemical and 
outcome data. The data consist of baseline values as well as outcome data rendering it 
suitable for a cohort design. The dataset and population is further discussed under the 
Method section.  
The product of epidemiological studies is validated based on the study’s design and its 
transferability to intended population. These two measures are often referred to as internal 
and external validity, respectively. Internal validity deals with the strength of the study 
design and its ability to predict causation and association. Contrastingly, external validity 
deals with whether association or causal relation between treatment and effect seen in the 
study population is true for of the target population.  
Randomized controlled trials (RCT) are considered the gold standard for 
epidemiological studies, because of their strong internal validity. Observational studies have 
lower internal validity as exposure is observed rather than introduced. By introducing 
exposure, RCTs enables the investigator to evaluate causation as the exposure is introduced 
in one group while no exposure or placebo is introduced in the other group. This allows the 
investigator to assume that an observed difference in outcome between groups is due to 
introduced exposure. Contradictory, in observational studies investigators are not able to 
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assume causation as participants are evaluated based on a pre-existing level of exposure 
with no controlled manifestation of exposure or outcome.  
In addition to the strength provided by introducing exposure, RCTs also gain internal 
strength over observational studies through randomizing subjects into exposure and control 
groups. In doing so, the distribution of confounders such as age and gender is expected to be 
similar between groups (confounders are discussed under limitations). Because the exposure 
groups are determined by preexisting levels of exposure in observational studies, 
confounders are not limited through randomization and has to be dealt with in other ways. 
The study’s applicability to a population is often referred to as the study’s external 
validity. The study population is in most cases only assumed to represent the entire 
population. Additionally, in some cases such as the Western Norway B-vitamin intervention 
trial (WENBIT) study and this current study, the study population may be different from the 
target population. For a study to external valid the differences between study group and 
target group can not alter the effect of exposure. In a case of high external validity the 
exposure or outcome are expected to behave identical in target population to what it did in 
the population under study. In this regard, RCTs do not have structural advantages over 
observational studies. 
1.3.1 Cohort design 
The cohort design is an epidemiological method where a population is followed up 
over time to evaluate the effect of one or numerous exposures on outcome (Figure 1). The 
population is divided into groups based on exposure at baseline, in this case plasma retinol 
level. The population can be divided further based on presence or absence of exposure or 
may be categorized based on level of exposure and then divided in to two or more groups, 
for example quartiles. The result of the cohort is gained through factoring the difference in 
risk of given outcome, in this case CVD death between exposure group. The hazard ratio (HR) 
is an indicator for the difference in probability of outcome between two or more groups of 
exposure [10, 11].   
The cohort design is similar to random controlled trial (RCT) in that they both 
evaluate risk of outcome between different exposure groups. Although, in a RCT, the 
participants are randomly selected into groups, which are then provided with exposure or 
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placebo. The participants are followed up and outcome is documented, leading to an 
evaluation of association and causation. In contrast, in a cohort design patients are divided 
in to groups according to pre-existing exposure. The lack of randomization and control over 
causation affects the internal validity of the cohort design. The reason randomization is 
performed in RCTs is to establish groups with identical risk of outcome. In a cohort design, 
randomization is not possible as exposure controls distribution of patients into groups. 
Confounding factors may therefore be more or less prevalent in certain groups limiting the 
power of results. Additionally, when exposure is observed rather than introduced only 
associations can be made, as there is no evidence of cause-effect [10].  
Figure 1, Cohort study design model, modified from Song et al. [11]. 
 
 
1.3.2 Association and causation 
Determining the level of association between exposure and outcome is the first step 
towards understanding a hypothesized link between the two. Association is whether one 
factor is found more commonly in the presence of another and is defined as different risk in 
the subsets of the population determined by the subjects’ actual exposure value. If we apply 
the concept to the cohort model we may ask; is the risk of an outcome higher in the group 
with exposure? Several epidemiological models and their statistical methods aim to explain 
Cohort Study 
design
Study population 
at baseline
exposure present
cardiovascular 
event
no cardiovascular 
event
exposure absent
cardiovascular 
event
no cardiovascular 
event
  
18  
 
whether two variables are associated, and if so, how strongly, and whether chance or other 
sources of bias can explain the observed association[12].  
Causation is an estimation that goes beyond association. The assumption of 
causation aims to explain relation between an exposure and following event or outcome. 
Unlike association measures, effects or causation cannot be directly computed. The lack of 
data should have explained if a participant’s outcome was affected or unaffected by the 
exposure. For example, if a patient receives a treatment and survives, there is no way to 
document what had happened if he did not receive the treatment.  
The cohort and RCT design can be used to illustrate the problem with causation. As 
mentioned above, in a cohort study, participants are categorized based on exposure and 
monitored for outcome (figure 1). However, there is no control over the onset of exposure 
or the effects of other contributing factors. In a RCT, onset of exposure is controlled by 
providing one study group with the exposure and another group placebo. Randomization 
reduces the effect of confounders, as both groups should have equal risk of outcome at 
baseline. The problem with evidence of causation over association is to prove that a 
participant would have had a different outcome result had he or she been in the other 
exposure group, illustrating the need of large study populations and significant numbers of 
outcomes [12]. 
1.3.3 Limitations of observational studies 
Epidemiological studies following a cohort design have several limitations and factors 
that has to be considered when constructing the model and evaluating the data. Sources of 
bias, confounding factors and chance will now be discussed [12].   
1.3.3.1 Bias 
In the context of evaluating clinical studies, bias refers to whether a measure of 
association between the exposure and the outcome is systematically wrong. In observational 
epidemiological studies such as our project, two main sources of bias are present, selection 
bias and information bias.  
Selection bias occurs in the design phase of an observational study, and is a potential 
source of bias although it is poses more of a problem in case-control studies than in cohort 
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studies. Selection bias occurs if the selection process introduces another, unintended 
systematic difference between the groups, and this systematic difference is associated with 
the exposure. In a cohort study, selection bias occurs if the investigator’s selection of 
exposed and reference groups introduces a systematic difference between the groups, other 
than the exposure, and that the systematic difference is associated with the outcome [10].  
In a cohort study, an error in measuring exposure or outcome may cause information 
bias. Information bias is referred to as either observational bias or misclassification. 
Observational bias is data recorded that does not accurately represent actual exposure or 
utcome, intentionally or un-intestinally. Missclassification, or Non-differential 
misclassification as seen in single classification of exposure or outcome. An example of non-
differential misclassification is the errors caused by mistyping. In contrast, differential 
misclassification in a cohort study is the degree or direction of misclassification depending 
on exposure status, or other variables [10, 11]. For example, the accuracy of serum retinol 
measurements might be lower for people with higher C-reactive protein (CRP) values.  
1.3.3.2 Confounding 
Confounding is a concept that aims to characterize the study subjects; patients with a 
certain characteristics tend to have certain exposures. The aim of an observational study is 
to examine the effects of the exposure, but sometimes the apparent effect of the exposure 
is actually the effect of another characteristic that is associated with the exposure and with 
the outcome.  The factor affecting the exposure or outcome is a confounder, provided it is 
not an intermediate step between the exposure and outcome. An example of this source of 
bias is CRP, as elevated CRP levels are proven to reduce serum retinol as well as being a risk 
factor of CVD. CRP then become a source of bias if CRP levels are different across serum 
retinol groups established based on exposure. There are two principal ways to reduce 
confounding in observational studies: (1) prevention in the design phase by restricting or 
matching, and (2) adjustment in the statistical analysis by either stratification or 
multivariable techniques. These methods require that the confounders are known and 
measured [10].  
As mentioned above, matching is one way of dealing with confounders. This 
procedure separates the population into different groups that are expected to have the 
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same value of potential confounders. The groups of the population are then matched based 
on age or gender. However, with increasing numbers of matching variables, the 
identification of matched subjects become progressively demanding [10].  
Adjusting the statistical analysis through the multivariate modeling is a method that 
simultaneously control for several variables to estimate the independent effect of each one. 
Usually, one of the variables in the model describes whether the outcome is observed, and 
the remaining variables describe the values of potential confounders. A multivariable model 
will estimate the effect of the exposure on the outcome, given that the exposed patient and 
reference patient are similar with respect to the confounders in the model. Models such as 
the Cox proportional hazard model are able to account for confounders, but are 
treacherous, because there is no limit amount and quality of variables you can enter into the 
model. All variables entered into such a model affects the outcome and distinguishing 
between confounding variables and variables creating noise is crucial for limiting of bias [10].  
1.3.3.3 Chance 
Chance is highly affected by sample size. If the investigator keeps adding to the 
sample size, the association will eventually become significant. Chance is a measure of 
accuracy of an estimate. Usually the precision of association between exposure and outcome 
is expressed as a confidence interval (CI, usually 95% CI). For a given association calculated 
for a sample population, the confidence interval is a range of values around the association 
which is believed to contain, within a certain probability (95% CI), the true value of that 
association. CI can be interpreted as the chance, which, with a 95% certainty, holds the true 
value of the association if the study is unbiased. Consequently, the wider the confidence 
interval, the less certain we are that we have estimated the strength of the association 
precisely [10, 13]. 
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1.4 Vitamin A 
Vitamin A is a fat-soluble vitamin that is essential to our diet and readily found in the 
highest concentrations in food sources such as liver, milk, strong colored vegetables, leafy 
greens and root vegetables. Absorption, distribution, metabolism, excretion, functions, toxic 
effects, diagnosis and relation with cardiovascular disease will now be discussed.    
1.4.1 Absorption 
Oral intake of vitamin A in form of retinol, retinyl esters and provitamin A-carotenoid 
food sources is essential for maintaining sufficient vitamin A levels in the body, as vitamin A 
cannot be synthesized de novo by humans [14]. Host vitamin A status depends on the 
sequence of digestion of vitamin A source foods, uptake into the enterocyte, and the 
handling of these substances inside the enterocyte. Uptake of retinol and provitamin A from 
the lumen is handled by the enterocytes and dependent on several factors within the lumen. 
These factors, dietary lipid consumption, bile salts and pancreatic lipase play essential roles 
as they create appropriate pH milieu and form mixed micells within the lumen to aid 
absorption [15, 16]. 
The key vitamin A sources absorbed from the diet; retinol, provitamin A-carotenoids, 
and retinyl esters (also known as retinol palmitate) have slightly different absorption 
pathways from lumen and through the enterocyte. Provitamin A-carotenes are either passed 
intact into the lymphatic circulation, cleaved and converted into a retinoid, or metabolized 
to an inactive species. As for the esterified and unesterified retinols, absorption from the 
lumen, through the enterocytes, leads to the lymph or portal system through a series of 
actions. Retinyl esters are hydrolyzed in the lumen by the pancreatic enzyme pancreatic 
triglyceride lipase and the intestinal brush-border enzyme phospholipase B. The mechanism 
of how unesterified retinol is absorbed by the enterocyte is not known. The unesterified 
retinol inside the enterocyte is paired with cellular retinol binding protein (RBP) type 2, and 
the complex provides substrate for re-esterification of the retinol thorough the enzyme 
lecithin retinol acyltransferase. The retinol esters enter chylomicrons together with other 
dietary lipids, which are released into the bloodstream and transported to the liver. 
Additionally, some of the unesterified retinol is also absorbed into the portal circulation, the 
mechanisms of the retinol transport protein facilitating the absorption is not known. 
Notably, regardless of being absorbed as esterified or unesterified retinol, retinol is at one 
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point unesterified in the enterocyte before complexed with RBP and further transported or 
re-esterified [15]. Notably, vitamin A supplementation of retinoids or retinyl esters are 
absorbed through endothelial cells, in which they joins the normal route of retinol in the 
enterocyte [15].  
1.4.2 Distribution 
The majority of total body vitamin A is in some form of storage (90%), with the 
remaining in active sites in peripheral tissues undertaking vitamin A dependent functions, 
and in the circulation system (10%). About 80 percent of vitamin A in storage is stored in the 
liver while the remainder of stored vitamin A is found at peripheral cites [15, 17].  
The circulatory system handles the transport of retinol. The chemical actors handling 
retinol during its distribution between entro- and hepatocyte, and the peripheral tissue are 
RBP, cellular-RBP (CRBP), cellular retinoic acid binding proteins (CRABP), retinaldehyde 
dehydrogenase type 2 (RALDH2) and additional enzymes such as retinoic acid receptor’s 
(RAR) and retinoid x receptor’s (RXR). The major routes of transport are between 
enterocytes and lymph system to the liver and its hepatocytes, as well as from the 
hepatocytes to active sites in the peripheral tissue. Recently absorbed retinol is released 
from CRBP of the enterocyte into the bloodstream where it joins the retinol-RBP-
transthyretin (TTR) complex. When the TTR complex arrives at the hepatocyte, retinol is 
released from the TTR and binds to CRBPs [15].  
Once inside the hepatocyte, the retinol-CRBP accumulates in the endoplasm of the 
cell until transport becomes available. The retinol-CRBP complex stores of the hepatocyte 
have two fates. Either retinol rejoins the circulatory system as part of the TTR complex or it 
is esterified to retinol ester by RALDH2 for storage. Retinol esters are transported within the 
liver to storage in the fat storing stellate cells. If serum transport complexes (TTR) are 
available, retinol joins a binding site TTR in serum to maintain the homeostatic level of 
serum retinol. The remaining CRBP attracts newly absorbed retinol if present, if not 
esterified retinol is freed from storage.  
In states of Vitamin A abundance, the presence of free RBP and synthesis new RBP is 
modest, and little if any newly absorbed vitamin A moves in to the liver causing further 
saturation in serum and peripheral tissue. In states of vitamin A deficiency, RBP 
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concentrations build up in the hepatocyte to bind and conserve available retinol, increasing 
absorption of serum retinol. Consumption of a vitamin A-rich meal translates into a major 
release of RBP-bound retinol to feed deprived peripheral tissue [15, 17].  
As opposed to retinol and its transport through the portal system, retinol esters are 
transported from the enterocyte of the digestive system to the hepatocyte of the liver 
through the lymphatic system. In the enterocyte, newly absorbed retinol esters are packed 
in chylomicrons before being released into the lymphatic system. The chylomicrons deliver 
the retinol esters to the hepatocytes, where they are further absorbed by lysosomes. In the 
lysosomes, the retinol esters are unesterified by acidic hydrolase and retinol is released into 
the cytoplasm to bind with CRBP for further distribution [15].  
The active metabolite of retinol, retinoic acid circulates in blood bound to albumin at 
a concentration nearly 1,000-fold lower then of retinol. Tissue pools of retinoic acid (RA) are 
rather short-lived requiring continual replenishment from circulating retinol and RA [18].  
1.4.2.1 Vitamin A reference values 
Sommer et al. states that there are three cut-off values sufficient to serve a purpose in 
determining vitamin A deficiency (VAD). VAD can be classified as liver stores below 0.07 
µmol/g or serum retinol concentration < 0.70 µmol/L. While the cut-off value of adequate 
vitamin A stores is at serum levels of > 1.05 µmol/L [19]. Brubacher et al. suggest that 
hypovitaminosis A with anaemia and functional abnormalities in adults, can occur as early as 
≤ 1.93 µmol/L [20]. The relevance of these values for this study are questionable as the 
majority of people with western lifestyles have vitamin A levels within the normal range 
given at serum levels of 500 - 1000 µg/L (2.41 – 4.83 µmol/L) [15].  
The prevalence of VAD in a population was initially set by WHO as the prevalence of ≥ 
5% with a serum retinol concentration < 0.35 µmol/L. The original classification was based 
on its association with the prevalence of eye signs of VAD. Because it was established that 
adverse effects of VAD occurred before ocular symptoms, the cut-off was reevaluated by the 
International Vitamin A Consultative group (IVACG), who suggested that in populations with 
≥ 15% of population with a serum retinol concentration of < 0.70 µmol/L is defined as 
significant prevalence of VAD. WHO later implemented the change in cut-off value [19, 21-
23]. Sommer et al. argues a wide acceptance for VAD beginning when liver stores of vitamin 
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A fall below 20 µg/g (0.07 µmol/g) as more accurate, and that serum levels may still be 
within the homeostatically regulated normal range [19].  
1.4.3 Metabolism 
The overview of vitamin A metabolism is structured on Solomon et al. chapter on 
vitamin A in Present Knowledge in Nutrition and the review article by Rhee et al. and is 
illustrated in figure 2  
Retinol is the predominant natural circulating retinoid. Retinol and retinyl esters are 
precursors for active retinoid isoforms, including all-trans, 11-cis, 13-cis, 9,13-di-cis, 9-cis, 
and 11,13-di-cis, with all-trans retinol being the predominant form. The pathway from 
absorption to active metabolite will now be discussed [15, 16].    
Vitamin A is stored in the liver as retinyl esters or found as retinol in cells or serum, 
while β-carotene is cleaved in to Vitamin A metabolites based on demand. Retinol 
undergoes two successive dehydrogenations at its carboxyl alcohol group to generate its 
active form retinoic acid. Retinol is initially converted to retinaldehyde by Alcohol 
dehydrogenases (ADH) or short-chain dehydrogenases (SDR). Additionally, retinaladehyde is 
converted to the active metabolite retinoic acid by retinaldehyde dehydrogenase (RALDH). 
Β-carotene is either symmetrically cleaved into two retinaldehydes or asymmetrically 
cleaved into one apocarotenal and further converted to retinoic acid. Conversion of retinoic 
acid back to retinol is not possible [15, 16].  
The all-trans retinoic acid is the metabolite product of the retinol metabolism 
pathway. Retinoic acid exerts the biological effects of retinoids by activating specific 
members of the steroid hormone nuclear receptor family, thus affecting steroid hormone 
controlled mechanisms such as metabolism, inflammation, immune function, and 
development of sexual characteristics. This family includes the RAR and RXR, and their 
subtypes indicated by the Greek letters α, β, and γ. RARs α, β, and γ bind both all-trans 
retinoic acid and 9-cis retinoic acid with high affinity [15, 16].  
While RXRs α, β, and γ only bind to 9-cis retinoic acid, the affinity of 13-cis retinoic 
acid is different, as it is not a ligand for retinoid receptors, but can be readily converted to 
metabolites with agonist properties.  The nuclear receptors RARα, RXRα, and RXRβ are 
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ubiquitously expressed, whereas RARβ, γ, and RXRγ exhibit tissue-restricted patterns of 
expression. The RAR regulates gene transcription through its participation in dimerization, 
either as a homodimer or as a heterodimer with partners for various nuclear receptors. 
Examples of RXRs heterodimeric partners are RARs, PPARs, vitamin D receptor, thyroid 
hormone receptor, the farnesoid X receptor, and liver X receptor. In the absence of RXRs 
heterodimic partners, RXR forms homotetradimers that are transcritionaly inactive but that 
are rapidly dissociated in to active dimmers in presence of ligand hormone receptors. The 
RAR-RXR heterodimer forms on two interfaces, the ligand binding domain, and the DNA 
binding domain. The complex then interacts with specific response elements in the 
regulatory region of targen genes [15, 16].  
Rhee et al. also reviewed studies evaluating the effects of individual RAR and RXRs 
absence to investigate effects of the individual RARs and RXRs, to further understand the 
specific effects of individual reseptor subtypes. Different mice models where used to 
evaluate the effect. RARα deficient mice show features of vitamin A deficiency, indicated by 
decreased viability, growth defects, and male sterility [16]. Observations from mice that 
were deficient in single RAR isotope suggested redundancy among RARs, and deficiencies 
where reversed by retinoic acid treatment.  The same effects where observed in RARβ and γ 
deficient mice. In contrast, RAR double mutants displayed multiple abnormalities and died in 
utero or shortly after birth. In RXR mutated mouse studies, the result suggests that RXRα has 
the ability to perform most RXR functions. It also suggests that when RXR deficient mice are 
born underdeveloped, the cardiovascular and  occular system is especially affected [16]. 
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Figure 2, flowchart of Vitamin A metabolism, provided by Rhee et al. [16] 
 
 
1.4.4 Excretion 
The primary excretion of vitamin A is through excretion of bile, with the net loss 
dependent on biliary volume. With increased hepatic stores, concentration in bile increases, 
potentially increasing vitamin A loss. Under normal circumstances, vitamin A loss in urine is 
fractional. Renal failure, multiple myeloma, febrile infection might lead to increased losses 
due to excessive urine production. The TTR complex and its ability as a form covalent bonds 
with other TTRs (homotetramer) is essential in preventing glomular filtration and urinary loss 
of RBP and retinol [15]. 
1.4.5 Cardiovascular disease related functions of vitamin A 
Vitamin A is a fat-soluble vitamin that is active in numerous functions in the body. 
Vitamin A and its active metabolites are important in processes like retinol pigmentation for 
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vision, mucine production, the immune system, reproduction, and intracellular 
communication. Furthermore, vitamin A metabolites act as ligands in signaling pathways of 
nuclear transcription, they activate cellular growth and differentiation, and improve 
bioavailability of iron. They also have antioxidative properties and anti-proliferation 
properties allowing them to act against proliferative disorders [15, 18, 24, 25]. The 
metabolites and functions of vitamin A that are deemed relevant for the atherosclerotic 
process and hence cardiovascular risk will be further discussed in this section. 
1.4.5.1 Retinoids and nuclear receptor functions 
Most of the functions of vitamin A is through active metabolites, also known as 
retinoids. The understanding of vitamin A’s functions beyond that of vision was improved 
with the discovery of nuclear receptors in the late 1980s. The family of nuclear receptors 
comprises of ligand-dependent transcription factors that regulate gene expression by 
binding to short DNA sequences near target genes. Six different receptors divided into 
groups were detected [14]. RAR and the isomer RXR each with three subtypes indicated by 
the Greek letters α, β, and γ, and the metabolic pathway from retinol to retinoic acid and 
RAR/RXRs has been discussed during evaluation of vitamin A metabolism. In vitro studies 
have demonstrated that all-trans retinoic acid and 9-cis retinoic acid are highly affinity 
ligands for RARs, whereas only 9-cis retinoic acid binds with high affinity to RXR.  
The retinoid receptors act through dimerization (combining of two molecules) to 
form homodimers or heterodimers. The binding of these dimers to hormone response 
elements coordinates the regulation of target genes by RAR ligands. The nuclear RARs 
function as heterodimers by complexing with one of the RXR, or as a homodimer binding to 
another RAR. These complexes bind to DNA sequences called RAR elements (RARE) or RXR 
elements (RXRE) located within the promoter of target genes. 
By activating these genes RAR carry out many different transcription functions 
through the recruitment of a host of positive or negative regulatory proteins, referred to as 
coactiavtors or corepressors, respectively. The net effect may either be gene repression, the 
release of gene repression, gene activation, or gene transrepression. The combination of 
receptors present in a cell will dictate the eventual outcome of the downstream 
transcriptome. In addition, the mixture of intracellular ligands will determine whether 
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RAR/RXR activation results in proliferation, apoptosis, differentiation or survival of cells. 
Over 500 genes have been suggested to be regulatory targets of retinoic acid. In some cases, 
the regulation of these genes have been shown to be direct, driven by liganded RAR-RXR 
heterodimer bound to a DNA response element. While in other cases the regulation appears 
to be indirect, reflecting the actions of intermediate transcription factors, nonclassical 
associations of receptors with other proteins, or even more distant mechanisms [14]. 
Important information about the role of the various RARs and RXRs has been 
obtained from several studies where one or several of the receptor genes have been deleted 
in mice. Many, but not all symptoms of vitamin A deficiency syndrome can be recapitulated 
in such mice. When mutations only affect one receptor subgroup, the mice survive and the 
abnormalities are minimal, suggesting a functional redundancy between various receptors 
and isoforms. In double mutant mice lacking either two RAR subtypes or RAR and RXRα or 
absence of multiple subtypes, the animals do not survive or have severe abnormalities [14, 
26]. Transcription regulation on the other hand involves further heterodimer formation 
between the RXR receptor and either thyroid hormone receptor or the peroxisome 
proliferator-activated receptor-gamma (PPARγ) [15]. 
1.4.5.2 Vitamin A’s effect on atheroclerosis 
Rhee et al. states that studies testing effects on human cardiovascular events have 
produced data showing vitamin A involvement in angiogenesis, cellular growth and oxidative 
balance. However, the results of clinical trials examining the effects of various forms of 
retinoids on cardiovascular events and mortality, have been conflicting [16]. 
In vivo evidence suggests that retinoids may influence arterial responses to injury and 
atherosclerosis. It is important to note that the processes of arterial injury, as might occur 
during coronary stenting, and that of atherosclerosis, are not the same although some 
overlap does exist in terms of the processes. Several studies have tested the effect of all-
trans retinoic acid on intimal hyperplastia/restenosis after vascular intervention in animal 
models. Streb et al. found that all-trans retinoic acid treated rats had 35 to 37% higher 
luminal area in the injured vessel compared with control after induced blood vessel injury 
[18]. Neuville et al. showed that all-trans retinoic acid inhibited proliferation and increased 
SMC migration at the site of vascular injury. All-trans retinoic acid also decreased the SMC 
  
29  
 
markers, consistent with decreased SMC differentiation [27]. These investigators also found 
that RARα, but not RXR agonists inhibited SMC proliferation and reduced carotid intestinal 
hyperplasia. 
1.4.5.3 Retinoic acid and atherosclerosis 
Some of the effects of vitamin A in the control of atherosclerosis might be assigned to 
effects of retinoids. Retinoids exert their biological effects on the atherosclerotic process by 
activating specific members of the steroid hormone nuclear receptor family, including RAR 
and RXR. RARs α,β and γ bind both all-trance retinoic acid and 9-cis retinoic acid with high 
affinity, while RXR α, β and γ only bind avidly to 9-cis retinoic acid. The retinoid 13-cis RA is 
not a ligand for retinoid receptors, but can be converted to one [16].  
Most data on nuclear receptors role in development is as mentioned, established 
through mouse experiments.  Kurakula et al. did a review in 2012 on the effects seen in 
studies evaluating nuclear receptor activity and atherosclerosis [28]. They found that nuclear 
receptors are proven drugable targets for intervention and even though nuclear receptors 
may not always affect metabolism beneficially in view of atherosclerosis risk, local nuclear 
receptor stimulation in the vessel wall through cell-type specific- or nuclear receptor-
subtype specific-activation, holds great promise for future treatment of atherosclerosis [28]. 
 Kurakula et al. argues that RAR-mediated atherosclerotic-protection involves 
decreased SMC proliferation, endothelial cell mediated vasodilation, increased endothelial 
cell survival and reduced foam cell formation. They also state that RXRs might only 
heterodimerize with nuclear receptors that have a beneficial role in endothelial cells, SMC, 
and microphages. Thus specific RXR agonists may also have great direct and indirect 
cardiovascular-protective properties [28]. 
1.4.5.4 Retionids’ effect on vascular smooth muscle cells 
Additionally vitamin A derived retinoids play important roles in vascular SMC growth, 
differentiation, and migration during the onset of atherosclerosis as well as under restenosis. 
During the early stages of vascular injury, medial vascular SMC migrate to the intima where 
they promote extracellular matrix deposition and reduce lumen size. The switch from a 
contractile to synthetic SMC phenotype, with decreased expression of SMC differentiation 
markers, may be central to the arterial response to injury. Recent evidence also 
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demonstrates that vascular SMC apoptosis may promote intimal hyperplasia, plaque 
formation and progression of disease. Thus, vascular SMCs are the key players in the normal 
vessel wall and pathologic response to injury and atherosclerosis [16]. Retinoic acid is 
believed to have effects on several functions and actions of SMC. It is suggested that retinoic 
acid alter SMC migration and proliferation, increases phenotype diversity and cell 
differentiation and regulates cell apoptosis [14, 16, 18, 28] 
Retinol has been shown to alter migration patterns of SMC. During the 
atherosclerotic process, SMC migrates from the media to the intima to further constrict 
blood flow in the provoked area of the vessel. According to Rhee et al. retinol has been 
shown to both increase and decrease migration of vascular smooth muscle cells (VSMC). It is 
reported that retinoids increase the expression of tissue plasminogen activator, a facilitator 
of cellular migration, and they have been implicated in increasing SMC migration. The 
findings were not supported by all-studies reviewed [16].  
However, retinoid may, according to Rhee et al., control VSMC proliferation, another 
major factor in vascular response to injury. Still, study results have not been conclusive. 
Retinoids do in some studies limit VSMC proliferation across study models of different 
animals. While in other, but similar studies, retinoids are reported to increase VSMC count 
and initiation of cell division (mitogenesis). The inconsistency in retinoid treatment response 
might differ depending on whether the cells are dormant or in a growth state. On example 
of the possible effects is that in rat aortic SMCs, all-trans retinoic acid stimulation alone 
increases cell number and mitogenesis. However, when the cells were stimulated in the 
presence of a mitogenic stimulus, cell numbers were reduced and proliferation suppressed 
[16].  
Another suspected mechanism of retinoids role in SMC proliferation was presented 
by Kurakula et al. They argued that RAR-antagonists inhibit lesion formation. The mechanism 
responsible was believed to be that RARα specific syntetic antagonis Am80, decreased SMC 
proliferation by inhibiting the activity of the transcription factor Krüpel-like factor 5 (KLF5), 
which is a key regulator in SMC activation. In the absence of ligands, RAR may form a 
transcriptional complex with KLF5 on the platelet derived growth factor promoter, leading to 
an increase in SMCs [28]. 
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1.4.5.5 Inflammation 
It is established that retinoids and especially retinoic acid also play a role in 
inflammatory responses in the body [15]. Studies in rats deficient in vitamin A exhibit 
increased inflammatory response [23]. Vitamin A and all-trans retinoic acid modulate hosting 
susceptibility to infection by interfering with both innate and adaptive immune function as 
well as host inflammatory responses. Retinoic acid effects the inflammatory response by 
down-regulating B-cell proliferation, T-cell proliferation, pro-inflammatory cytokines and C-
reactive proteins [23]. 
Vitamin A deficient mice have defects in helper T-cell activity. In addition, retinoic 
acid inhibits T and B-cell proliferation, although evidence of the opposite effects also exist 
[23]. Retinoic acid may also inhibit B-cell apoptosis through RAR responses, as well as 
modulating antigen presentation by exerting direct effects on dendritic cells function. For 
example, retinoic acid enhances dendritic cell maturation and antigen-presenting capacity 
via RXR receptors, in the presence of inflammatory stimuli such as tumor necrosis factor 
(TNF) [16]. 
In addition to the mentioned functions, retinoic acid controlled expression of 
numerous proinflammatory cytokines. In human monocytes, retinoic acid suppressed the 
granulocyte-machrophages that produces activin A, a protein that enhances 
proinflammatory biosynthesis. In contrast, retinoic acid induced interleukin (IL) 1β 
production and inhibited IL-1 receptor antagonist expression in activated monocytes. In 
macrophages, retinoic acid inhibited endotoxin, IFN-γ, and phorbor ester-induced TNF 
production. Furthermore, in lipopolysaccharide-stimulated machrophages, retinoic acid was 
found to inhibit IL-12 production. In general, suggest that retinoic acid may limit 
inflammation by repressing chemokine production [16, 23].  
Recent work also implicates retinoids in regulating endothelial adhesion molecule 
expression, an inflammatory response involved in early stages of atherosclerosis. Retinoid 
acid suppresses TNF-stimulation of vascular cell adhesion molecule-1 (VCAM1) in endothelial 
cells, with reduced VCAM1 dependent T-cell binding [16, 29].  
CRP is an inflammatory biomarker associated with increased CVD risk. CRP 
production is regulated primarily by IL-6 in liver, CRP production may also occur on sight in 
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vascular lesions. Retinoic acid is known to antagonize NF-IL6, a transcription factor involved 
in regulating IL-6 production. An inverse relationship had been observed between retinol 
and CRP levels during inflammation and will be further discussed in a later section [16].  
1.4.5.6 Antioxidative properties 
A vital property of vitamin A is its antioxidative action, and Blomhoff et al. reports 
that Vitmain A deficiency promotes inflammatory reactions [14]. Actions include protection 
against reactive oxygen species (ROS), ability to quench singlet oxygen, and trapping and 
neutralizing free radicals. Vitamin A’s bind to single oxygen particles and free radicals 
disallowing them to react with polyunsaturated fatty acids contained in lipids of cell 
membranes. Thus reducing the preoxidative damage the free radical could have caused cells. 
At the same time vitamin A suppresses the activity of participating enzymes in the 
peroxidation of these lipids, and it as prevents oxidative disorders of protein glycosylation in 
cell membranes [14, 24].  
1.4.6 Toxicity 
Excessive vitamin A intake may result in toxicity rapidly or over time. Allowing total body 
vitamin A to exceed the limited storage capacity of the liver, may lead to the supersaturation 
of the body with vitamin A and the poisoning referred to as hypervitaminosis A. As the 
hepatic cells fail to absorb available Vitamin A, tissue build up occurs, leading to toxic effects 
[14, 15].  
The upper tolerable limit (UL) for adults is 3000 µg/day of vitamin A [15]. 
Hypervitaminosis A has been linked to blood levels of vitamin A above 1.0 mg/L (3.5µmol). 
Toxic effect appears when the liver no longer can absorb excess vitamin A from the blood 
stream and there is no more serum retinol binding protein (RBP) to bind free retinol 
molecules. Toxic effects are seen after intake of 150-1200 mg (500 000-4 000 000 IU) of 
vitamin A over two days by adults, after single dose of 45 mg (150 000 IU) by school-age 
children, or after intake of about 22 mg (75 000 IU) by small children [24]. There have been 
reports of children given as much as 500 000 IU by mistake in nyctalopia (night blindness) 
prevention programs [30], resulting in fatalities, and extreme cases such as polar explorers 
consuming polar bear liver (Vitamin A content of approximately 10 mg/g). Additionally high 
doses of vitamin A should be avoided for patients with liver failure and cirrhosis or in-bile 
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ducts obstruction, because of an increased risk of toxic effects. Pregnant women should 
avoid high doses of vitamin A, as it may contribute to fetal development anomalies [24]. 
Patients with hepatic and renal disease and children are especially susceptible to the adverse 
effects of this vitamin. The supplementation with provitamin A, i.e. β-carotene, could be 
assumed to be safer, as conversion of β-carotenes to retinol is regulated by serum retinol 
concentration. However, Bjelakovic et al. performed a meta-analysis of 53 trials with low risk 
of bias on beta-carotene, vitamin E, and vitamin A supplementation. They concluded that 
supplementation with beta-carotene in doses higher than the recommended daily allowance 
(RDA) seems to significantly increase mortality [31].  
Hypervitaminosis A can take the form of acute or chronic poisoning. 
1.4.6.1 Chronic poisoning 
Hypervitaminosis A in the form of chronic poisoning have the following symptoms; chronic 
fatigue, irritability, double vision, sleep disturbances, renal dysfunction (haematuria), and 
edemas. Additionally high intake of vitamin A over a period may disrupt the absorption of β-
carotene and mineral salts. Excessive intake of vitamin A is also harmful to the osteoarticular 
system. It may lead to joint and spine pains, as well as decalcification of bones [24]. Studies 
have indicated although not consistently, an increased risk of fractures in populations taking 
vitamin A supplements [24, 32-34]. 
1.4.6.2 Acute poisoning 
The symptoms of acute poisoning, the other form taken by hypervitaminosis A, are general 
weakness, dizziness and severe headache, increased intracranial pressure, nausea, vomiting, 
hepatosplenomegalia (enlargement of liver and spleen), and after a few days skin changes 
[24].  
1.5 Diagnosis of vitamin A status  
Liver stores of vitamin A are considered the gold standard for total body vitamin A. 
Measurements of liver stores are highly invasive and seen as unfeasible in humans. Among 
several biomarkers, serum retinol levels are frequently used. Serum retinol is regulated by 
the prevalence of retinol binding protein (RBP) in the hepatocytes [15, 17]. The regulation of 
RBP in the liver affects serum retinol and creates a plateau stabile serum retinol 
concentration, while liver stores of vitamin A metabolites may fluctuate. However, there are 
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multiple factors that affects serum retinol independent of liver stores (zinc deficiency, CRP, 
estrogen and corticosteroids). Additionally the relation between liver stores of vitamin A and 
serum retinol is not linear [17]. The historical and current method to measure vitamin A 
status utilizes its fluorescence properties. The method currently in use is a combination of 
liquid chromatography and tandem mass spectrometry. During preparation, the samples 
were protected from heat, light, oxidizing substances to prevent denaturing [35].  
Figure 3, Hypothetical relationship between mean plasma vitamin A levels and liver vitamin A concentration, provided by 
Olsen et. al. [17], original reference values of mean plasma vitamin A axis (Y) have been altered from µg/dl to µmol/l. 
 
1.5.1 Serum retinol as a biomarker 
A biomarker is defined by the Biomarkers of Nutrition for development (BOND) as: “A 
biological characteristic that can be objectively measured and that serves as an indicator of 
normal biological processes, pathogenic processes, or responses to therapeutic 
interventions. Biomarkers can be broadly characterized into three groups: those that 
measure physical or genetic traits, those that measure chemical or biochemical agents in the 
biological system (serum retinol, iron, zinc), and those that assess a measureable physical 
function or future clinical risk” [25]. The limitations and effectiveness of serum retinol as a 
biomarker will now be discussed. 
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Serum concentration stays within a narrow range in individuals with adequate liver 
vitamin A stores. Serum concentration will only fluctuate outside this range under certain 
conditions. As liver stores become depleted, serum retinol will decrease and when total 
body vitamin A exceeds the hepatocytes holding capacity serum retinol will increase. As 
stores become depleted the liver cells absorb available retinol, reducing the serum 
consentration [15]. The BOND report by Raiten et al. builds on the relation between liver 
vitamin A stores established by Olson et al. by stating that serum retinol serves as a strong 
indicator for assessing deficiency and toxicity in individuals and populations with serum 
levels outside the livers homeostatically controlled range [17, 25]. Although its ability to 
estimate intake and exposure is weak, as there are large variations in individual responses to 
doses of retinol [17]. Raiten et al. (2011) also assess the utility of serum retinols for assessing 
exposure, status and function [25].  
Raiten et al. reported that serum retinol reflects long-term intake, but is not sensitive 
to acute changes. As for vitamin A status serum retinol can be utilized as an indicator of 
severe and moderate vitamin A deficiency, but is not as widely accepted and used for 
assessing toxicity. As for serum retinols functionality, low serum concentration is historically 
used to assess eye function. A concentration of 0.48 µmol/L is elected as a lower cut-off 
because of its association with xerophtalmia, although no direct cut-off values are 
established were morbidity/mortality effects begin to occur [25]. No cut-off value for toxicity 
has been established but as mentioned In the vitamin A toxicity section, Hypervitaminosis A 
have been linked to blood levels of vitamin A above 1.0 mg/L (3.5µmol) [24]. 
Tanumihardjo et al. and the Vitamin A Tracer Task Force have provided an evaluation 
of the quality of biomarkers of vitamin A status in relation to liver reserve concentrations.  
The ability of the different indicators and biomarkers to predict total body vitamin A levels is 
displayed in Figure 4. The bars of the graph in figure 4 indicate to what degree the indicator 
can predict vitamin A status. Because of the previously discussed homeostatically controlled 
relation between, serum retinol only reflect deficient and marginal total vitamin A stores 
[36]. 
  
36  
 
Figure 4, Effectiveness of different biomarkers of vitamin A, provided by: The Vitamin A Status Continuum [36] 
 
The association between vitamin A status, liver reserves, and the indicators currently used. Clinical tests include 
xerophthalmia, night blindness, and dark adaptomertry. Breast milk is specific to lactating woman. Dose response test 
includes both relative dose response and modified relative dose response. The tracer dilution technique is the only method 
that provides a quantitative estimate of total body vitamin A pool size. The Figure was originally printed by the Vitamin A 
tracer task force [36].    
1.5.1.1 Acute phase response 
An acute phase response to infection, trauma, surgery or other illness is associated with a 
reduction in serum retinol and other micronutrients. The reduction of serum retinol might 
be a result of the increased capillary permeability. Hence, the change in the serum retinol 
seen does not reflect changes in liver or total body vitamin A stores, which are expected to 
be unaffected [37]. The cross sectional study my Duncan et al. discuss the magnitude of 
systematic inflammatory response effect on serum micronutrients consentration. They 
suggest that the increase in permeability allows retinol-binding protein (RBP) to migrate and 
subsequently reduce serum retinol [38]. Their study indicated that retinol was lower when 
CRP concentrations were modestly elevated, as indicated by a serum level of CRP between 
10-20mg/L. While CRP concentrations of >80mg/L were associated with the largest decrease 
in vitamin A status with a median decrease in serum levels of 25 - 75 %.The observations by 
Duncan et al. support previous assumptions concerning the link between systemic 
inflammation response and serum retinol concentration [38].  
The same effect reported by Duncan et al. was documented in the meta-analysis 
performed by Thurnham et al. (2003). They calculated that during mild infection or early 
convalescence only 76% of total body vitamin A is represented by plasma levels, giving a 
underestimation of vitamin stores of 24% [23]. No method of adjustment for this effect has 
been established, and the reduction of serum retinol in patients with elevated acute phase 
proteins was acknowledged as a confounder for CVD by the BOND report by Raiten et al. 
  
37  
 
(2011) as both reduced serum retinol and elevated CVD risk is expected in populations with 
elevated CRP [25].  
1.5.1.2 Obesity 
Obese people have lower plasma retinol levels than participants within normal 
weight range. The origin of this association might be a result of the increased systemic 
inflammation response seen in obese populations when compared to non-obese [15]. 
Derosa et al. conducted a study on 363 obese (body mass index (BMI)>30 kg/m2) participants 
with normal glucose tolerance. Participants with confounding factors of cardiovascular risk 
where excluded from the study (smokers, diagnosed with CVD within last 12months, familiar 
and/or severe dyslipidemia, and stable hypertension under drug treatment). When 
compared with a non-obese control group Retinol binding protein-4, leptin, IL-6, and CRP 
were significant lower in the non- obese group at p<0.0001. Vaspin, resistin, and TNF α were 
significantly lower in the non-obese group at p<0.05. The data suggest that obese subjects 
are more likely to have higher levels of inflammation and insulin resistance adipocytokines 
compared to non-obese [39]. In which indicates that the association between low serum 
retinol and obesity may be caused entirely or partly through the increased inflammation. 
1.5.1.3 Smoking 
Another factor is smoking which is found to reduce serum levels of several antioxidant 
micronutrients, in particular Vitamin C, E, and the pro-vitamin A β-carotene [15]. The review 
article by Alberg et al. evaluated the influence of cigarette smoking on circulating 
concentration of antioxidant micronutrients, thereby also vitamin A. the review indicated 
that smoking significantly lowers circulating micronutrients. Some of the mechanisms among 
smokers discussed as contributers were; altered diet habits, increased inflammation and 
increased oxidative stress. They also found that low exposure also reduced serum 
micronutirents [40]. The decrease seen at low exposure indicating a need to assess smoking 
exposure beyond being a smoker or not. 
 Cotinine is an alkaloid found in tobacco and is used as a metabolite of nicotine. Self-
reporting is known to misclassify or underestimate the smoking population by 1% to 4.2% 
[41]. Cotinine is a principal metabolite of nicotine, with a half-life of approximately 20hours. 
Inhalation of nicotine among smokers may differ depending on brand of cigarettes and 
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habits. Wei et al. argues that cotinine represent the nicotine reaching the bloodstream, 
possibly reducing margin of error [41]. A combination model of self-reported smoking habits 
and plasma cotinine was used to classify smoking exposure in the WENBIT and BECAC 
studies [42]. 
1.6 Previous vitamin A and CVD studies 
The association of CVD with the lower end of this range of plasma levels (< 600 µg/L or 
2.9 µmol/L) suggests that a reevaluation of the normal range might be in order [43]. Largely 
as the effect of subclinical levels of vitamin A is not fully understood, as no efficient method 
of measuring this range is established [25]. Vitamin A and CVD have been studied in 
prospective cohort studies, in healthy, elderly and in case control studies. Reviews and 
studies found relevant are discussed in this section.  
The study by Goyal et al. 2013 looked at the hazard ratio of cancer, CVD and all-cause 
mortality in 16008 participants of the National Health and Nutrition Examination Survey III 
(NHANES III) population across plasma antioxidants. 4225 died over a median follow-up of 
14.2 years (891 cancer-related and 1891 CVD-related deaths). The population was grouped 
into quintiles based on plasma antioxidant concentarations. The study found a decreased 
CVD-related HR in the middle quintiles (HR: 0.78 – 0.90) and an increased HR in the upper 
quartile of plasma retinol concentration (HR: 1.08) with the lower quartile as the referent, 
none of the assumptions where significant. Adjustment for confounders did not substantially 
change the assumptions. As for all-cause mortality the HR was lower in all four quartiles (HR: 
0.73 – 0.95) with the lower quartile as the referent. All the assosiations of reduced HR for all-
cause mortality were significant before adjustment. After adjustment all none of the 
associations changed, however, significance was then only 3rd and 4th quartiles [44]. 
Brazionis et al. reported in 2010 from the Melbourne Collaborate Cohort Study 
(MCCS), where they reported hazard ratio of CVD across tertiles of plasma retinol. The study 
included 441 community-dwelling adults from the MCCS population. Their results suggested 
an increased hazard risk of CVD in the group with plasma retinol levels below 2.24 µmol/L, 
when adjusted for age, gender, diagnosed diabetes, self-reported heart condition, plasma 
cholesterol, plasma triglycerides, plasma homocysteine, plasma CRP and urinary albumin 
excretion rate [7].   
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The Prospective epidemiological study of myocardial infraction (PRIME) study was 
presented by Gey et al. in 2008 and suggested that plasma retinol levels of <601 ug/L (2.90 
µmol/L) in a fifth of middle-aged European men placed them at an approximately threefold 
risk of developing coronary heart disease. The PRIME study included 10600 50- to 59- year 
old males from Western-European countries. The study compared retinol levels between an 
exposure group of 150 males that experienced fatal (N=27) or non-fatal (N= 123) coronary 
heart disease and a control group of 285 randomly selected participants [43].  
Reimersma et al. did a case-control study in 1991 on 110 volunteers with stabil 
angina pectoris and 382 controls. The case-control study aimed to investigat the relation 
between risk of angina pectoris and plasma concentration of Vitamin A, C and E. No 
significant relation between plasma levels of vitamin A and risk of angina pectoris was found 
[45].  
Rhee et al. 2012 reviewed studies evaluating atherosclerotic development from a 
clinical perspective. The studies evaluated were the PRIME study, CARET study, women’s 
health study, the meta-analysis by Bjelakovic et al. also discussed in section 1.6.1 and a study 
of gene expression mechanism by Kraan et al. [16, 46].  The data presented in the studies led 
Rhee et al. to conclude that retinoic acid may modulate atherosclerosis in humans by 
altering gene expression and that retinoids effect on CVD are important [16]. 
1.6.1 Vitamin A Supplementation reviews 
Two independent meta-analysis were performed in 2013 to evaluate the effect of 
Vitamin A and carotene supplementation. The meta-analysis by Bjelakovic et al. evaluated β-
carotene, vitamin A and vitamin E supplementation and its effect on all-cause mortality. The 
meta-analysis included 53 randomized trials with low risk of bias. These showed that the 
dose of vitamin A was significantly positively correlated with all-cause mortality. The second 
meta-anlysis, was performed by Myung et al. evaluated vitamin and antioxidant 
supplementation and CVD risk. The meta-analysis included 50 randomized trials with low risk 
of bias. Their conclusion was that there is no evidence to support the use of vitamin and 
antioxidant supplements for prevention of CVD [31, 47, 48].  
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2 Hypotheses 
In this study, we will compare vitamin A status and future cardiovascular mortality risk in 
patients who previous underwent coronary angiography for suspected Coronary artery 
disease (CAD) at Haukeland University Hospital, Bergen, Norway (HUS) and Stavanger 
University Hospital, Stavanger, Norway (SUS).  
The objective of the study will be to investigate possible associations between cardiovascular 
mortality risk and subclinical deficient and toxic plasma retinol concentration.  
It is hypothesized that serum retinol concentrations at the extreme ends of the distribution 
are associated with increased risk for fatal cardiovascular endpoints and for total mortality. 
 
3 Method 
3.1 Population under study 
BECAC  was established in 1999 to 2004 through the Western Norway B-vitamin 
intervention trial at Haukeland University Hospital and Stavanger University Hospital. The 
population available for this study consisted of patients recruited through the Bergen 
Coronary Angiography Cohort (BECAC) and the Western Norway B Vitamin Intervention Trial 
(WENBIT; ClinicalTrails.gov number NCT00354081) as explained by Svingen et al [42]. As 
WENBIT participants were included and part of the BECAC population, the population under 
study for this project will be referred to as the BECAC population. 
The original BECAC population consisted of 4150 adults who underwent coronary 
angiography at the Department of Heart Disease, HUS, between January 2000 and April 
2004. The primary aim of the BECAC study was to study various prognostic markers of 
cardiovascular end-points and cause specific mortality in patients with suspected heart 
disease. Furthermore, BECAC established the source population of patients randomized for 
from WENBIT study at HUS.  
The aim of the WENBIT study was to investigate the effect of B vitamin 
supplementation on mortality and cardiovascular events [49]. Across the population, only 
those patients admitted due to suspected stabile angina pectoris (SAP) (n=3413) were 
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selected for the BECAC study, of whom 1822 (53.4%) were enrolled in WENBIT. Additionally 
751 participants of the WENBIT study with SAP and angiographically verified coronary artery 
disease (CAD) were recruited to the BECAC population, from SUS. The study population was 
monitored for the occurrence of acute myocardial infraction (AMI) until December 31st 2006 
[42]. Patients with missing baseline covariates specific for this project were also excluded 
(n=308), resulting in a total population of 3842 as illustrated in flowchart (figure 5).  
   
Figure 5, Flowchart of study population and retinol deciles 
 
3.2 WENBIT supplementation 
The patients recruited from BECAC for WENBIT, received folic acid, vitamin B6 or B12 
(alone or in combination) or placebo for a median of 38 months [49]. The WENBIT study is a 
double-blinded study on the clinical effects of homocysteine-lowering therapy in patients 
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undergoing coronary angiography for suspected CAD. A 2 x 2 factorial design was used in 
order to assess the effect and combination of folic acid/vitamin B12 and separately vitamin 
B6 versus no vitamin B6. Baseline characteristics used for the current study was gathered 
before patients received intervention, additionally the original WENBIT supplementation 
intervention did not significantly change; mortality, risk of CVD or alter biomarkers of CVD 
such as IL-6 and CRP [50].  
3.3 Baseline Characteristics of participants  
 Baseline characteristics and information regarding patients’ lifestyle and medical 
history were obtained through self-administered questionnaires and verified by comparing 
self-reported status with hospital records [42]. Hypertension and diabetes mellitus were 
defined according to preexisting diagnosis, and patients were classified as diabetic or non-
diabetic regardless of having type 1 or type 2. Patients were classified as smokers if they 
were self-reported as current smokers or having quit within the last four weeks, or if 
patients had plasma cotinine ≥85 nmol/L. The classification “Physical active” included 
patients self-reporting being physically active twice or more per week. Trained nurses 
performed blood sampling, blood pressure measurements and assessment of 
anthropometric data. Left ventricular ejection fraction was obtained either by 
echocardiography or by ventriculography performed during cardiac catheterization [42]. 
3.4 Food Frequency Questionnaire  
Dietary intake assessment was performed at baseline and only in a sub-group of the WENBIT 
population, consisting of those recruited from Bergen. Food frequency questionnaires (FFQ) 
were provided for the patients and returned in hand or through mail. The FFQ used for the 
assessment of WENBIT patients were developed at the Department of Nutrition, University 
of Oslo (UiO) [51].  
 The FFQ included 169 food items that were grouped according to Norwegian meal 
patterns and was designed to obtain information on usual food intake during the year prior 
to the study. The frequency of consumption was given per day, week, or month, depending 
on the food item in question. The portion sizes were given as household measures or units 
such as slices or pieces. [51].   
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 The FFQ also included questions about supplement intake, including cod liver oil, cod 
liver oil capsules, and fish oil capsules. Supplement intake was categorized in three groups: 
whole year or winter use only, number of times per week, and amount per time. Nutrient 
intake was calculated by using the database and software developed by the Department of 
Nutrition, UiO (Kostberegningssystemet, version 3.2; UiO, Norway)[51]. 
 The FFQ was returned by 2484 (80.4%) of the patients randomly assigned to the 
WENBIT. Nineteen questionnaires were excluded because they contained more than one 
blank page. Patients with very low (<3000 kJ or 717 kcal for woman and <3300 kJ or 789 kcal 
for men) or very high (>15,000 kJ or 3585 kcal for woman and >17,500 kJ or 4182 kcal for 
men) estimated daily energy intake were excluded (n=53), leaving FFQ data of 2412 patients 
to be included in the study [51]. The correlation regression with plasma retinol was 
performed with 1917 patients as a further 95 was excluded due to missing data. 
3.5 Blood Collection and Biochemical Analysis 
For BECAC patients undergoing coronary angiography at HUS, venous blood samples were 
drawn at baseline, usually 1-3 days before the procedure, while BECAC patients undergoing 
coronary angiography at SUS had samples drawn immediately after the procedure. Blood 
sampling was carried out around noon in most patients. No relationship between patients 
time of last meal and blood results was found and blood samples were therefore assumed to 
be unaffected. Routine laboratory analyses were performed at the hospital laboratories at 
HUS, or at SUS respectively. Estimated glomerular filtration rate (eGFR) was obtained using 
the Chronic Kidney Disease Epidemiology Collaborate formula [42]. For study-specific 
analysis, serum and plasma were immediately prepared and stored in 2mL Vacutainer tubes 
(Becton, Dickinsona and Company, United States) at -800C until thawed and analyzed by 
laboratory staff blinded to the clinical outcomes of the patients. Serum cotinine were 
analyzed using liquid chromatography-tandem mass spectrometry at Bevital AS, Bergen, 
Norway (http://www.bevital.no) [35, 42]. Serum CRP was measured using an ultrasensitive 
immunoassay, with a detection limit of 0.17 mg/L, applying Behring nephelomer II system 
(CV 8.1-11.4%; N latex CRP mono, Behring Diagnostics, Marburg, Germany), respectively 
[42]. 
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3.5.1 Plasma retinol data 
Plasma retinol was elected as biomarker for patients’ vitamin A status. Status was 
defined based on blood samples taken at enrolment. Patients’ plasma retinol concentration 
was measured and determined using an automated high-performance liquid 
chromatography tandem mass spectrometry (HPLC/MS/MS) assay developed by Bevital A/S 
in collaboration with the Section for Pharmacology, Department of Clinical Medicine at the 
University of Bergen (UiB) and Laboratory of Clinical Biochemistry, HUS [49]. Midttun et al. 
2011 found the assay suitable for analysis of established markers of fat-soluble vitamins A, D 
and E in 50 µL of human plasma for the BECAC population. The assays are suitable due to the 
limited amount of plasma available for analysis and due to its precision and repeatability 
[35].  
3.6 Clinical End Points 
For the evaluation of plasma retinol levels and CVD risk, all-cause death, coronary 
heart disease related death and non-coronary heart disease related death, endpoints were 
used to investigate hazard risk. 
 According to Svingen et al. endpoint data was obtained from the Cause of Death 
Registrary at Statistics Norway (http://www.ssb.no) and the Western Norway Cardiovascular 
Registery [42, 52, 53]. The latter contains all CVD discharge diagnosis from the patient’s 
administrative systems at Western Norway public hospitals. Medical records were used to 
verify the registered data. The revised European criteria published in 2000 were applied to 
classify AMI, including both fatal and non-fatal events, and the study end point was assigned 
by the WENBT study end-point committee [42, 54]. If death occurred ≤28 days after the 
onset of an event, the event was classified as fatal. Acute myocardial infraction was 
classified according to the diagnostic criteria of the revised definition of myocardial 
infraction published in 2000 [51].  
 Causes of unstable angina pectoris were classified as endpoints if patients were 
urgently admitted to hospital due to acute attacks of typical ischemic symptoms 
accompanied by electrocardiographic ST-T findings of myocardial ischemia at rest and/or if 
coronary angiography during the same hospital stay verified significant progression of their 
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CAD. Endpoints were recorded in WENBIT and BECAC until December 2005 for this study. 
Members of the endpoint committee adjusted all events [51]. 
3.7 Ethics 
The WENBIT and BECAC studies followed the guidelines of the Declaration of Helsinki and 
were approved by The Regional Committee for Health Research Ethics and The Norwegian 
Data Inspectorate. All Participants provided written informed consent [35, 42, 49]. 
3.8 Data analysis 
3.8.1 Description of variables 
The variables that will be used during the statistical analysis are listed in Table 1, with 
associated abbreviation, units, and description. Values are included due to their role in Cox 
regression analysis. 
Table 1, Description of variables for survival analysis 
Variable Abbreviation unit Description 
Body mass index BMI kg/m2  
Plasma retinol  µmol/L  
Age  years  
Gender  0/1 Categorical variable, 0=male/ 
1=female  
C-reactive protein CRP mg/L  
Estimated 
glomular filtration 
rate 
eGRF mL/min/1.73m2  
Apolipoprotein A1 ApoA1 g/L  
Diabetes DM 0/1 Categorical variable, 0=No DM/ 1 = 
DM 1 and DM 2 
Statin therapy Statin 0/1 Categorical variable, 0= no 
treatment/ 1= treatment aimed to 
reduce cholesterol ≥20% 
Physical activity  0/1 Categorical variable, 0= not active/ 
1= self-reporting being active twice 
or more per week 
Smoking exposure Smoking 0/1 Categorical variable, 0= no 
exposure/ 1= current smokers or 
having quit within the last four 
weeks, or if patients had plasma 
cotinine ≥85 nmol/L 
Systolic blood 
pressure 
SBP mmHg  
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3.8.2 Statistical analysis 
All statistical analysis was performed using IBM SPSS Statistics for Windows, version 
21 (SPSS, Chicago, IL, USA). Because of the  large sample size (>30) the sampling distribution 
is assumed to be normally distributed [13]. Spearman correlation analysis was performed on 
to evaluate the relation between plasma retinol with confounders and food intake 
documented by the FFQ. For categorical variables such as smoking exposure, physical 
activity, gender, statin therapy, and diabetes, independent sample T-tests were used to 
assess difference in mean plasma retinol concentration between exposure groups of the 
categorical variable. ANOVA was used to assess the difference in means between plasma 
retinol deciles. P-values below .05 were regarded to be significant. 
3.8.3 Survival analysis 
Kaplan-Meier and Cox regression model were used to assess the association of plasma 
retinol concentrations and the risk of total mortality, cardiovascular mortality and non-
cardiovascular mortality.  Kaplan-Meier was used to investigate the number of days patients 
were under study.  
Three different models were established: First, plasma retinol was used as a continuous 
variable. In a second approach, plasma retinol was divided into quartiles, and the third 
approach used the extreme deciles (1st and 10th deciles) compared to the 2nd to 9th deciles 
(middle deciles).  
In the Cox regression analysis, we used different adjustments: the first model analyzed the 
effect of plasma retinol in a crude model without adjustments (model 1). Model 2 included 
adjustment for age (in years) and gender. Model 3 included further adjustments for C-
reactive protein, eGFR and apolipoprotein A1. The final model 4 included further 
adjustments for history of diabetes mellitus (in categories), use of statins (in categories), 
physical activity (in categories), smoking (in categories), body mass index and systolic blood 
pressure.  
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3.8.4 Plasma retinol categories 
Because of the initial survival analysis findings already discussed and the objective of 
evaluating the association between subclinical plasma retinol concentrations and CVD risk, 
deciles was elected for grouping the population. The 2nd to 9th deciles will be used as the 
reference category and compared to the 1st and 10th deciles. The 2nd to 9th deciles will from 
now on be referred to as the middle deciles. Deciles were deemed desirable, as the 1st and 
10th deciles is expected to include patients with plasma retinol concentrations outside the 
homogenically controlled range of plasma retinol previously described. Cut-off values for 
deciles are presented in Table 2, Cut-off values for plasma retinol deciles 
Table 2, Cut-off values for plasma retinol deciles in the present study 
 1st decile Middle deciles 10th decile 
Number of patients 395 3081  368 
Retinol values ≤ 2.15 µmol/L 2.15 to 3.81 µmol/L ≥ 3.81 µmol/L 
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4 Results 
4.1 Population characteristics 
Of the 4150 of the original population 3842 patients were included in the data 
analysis, giving a participation percentage of 92.6%. 308 patients were excluded before data 
analysis due to missing variables.  
The study population is described in Table 3. The average age was (mean ± SD) 61.7 ± 
10.3 years, and 72.4% were male. On average, the population was overweight with a BMI of 
26.8 ± 3.95 kg/m2, 80% received statin therapy, 80% were physically active by self-report, 
and 11.5% had type 1 or 2 diabetes.  
The average plasma retinol concentration was 2.90 ± .694 µmol/L with a range from 
0.41 µmol/L to 9.11 µmol/L. One patient had a plasma concentration indicating vitamin A 
deficiency and two patients had inadequate levels, while 17.3% had plasma retinol levels of 
above 3.50 µmol/L (which according to Rutkowski et al. indicates risk of hypervitaminosis A, 
reference values are discussed in section 1.4.1 and 1.5.1). 
 
Table 3, Descriptive data for cardiovascular risk factors in BECAC patients, as in the total 
population and for men and women separately. 
Parameters Total (N=3842) Male (N=2784) Female (N=1060) 
Plasma retinol  2.90 ± .694 a  2.92 ± .682  2.86 ± .725  
DM 11.5%  11.8%  10.9%  
Physical activity 74.9%  76.0%  71.9%  
Smoking 25.8%  27.0%  22.7%  
Statin 80.1%  83.8%  27.3%  
Age 61.7 ± 10.3  61.2 ± 10.2  63.2 ± 10.5  
ApoA1 1.31 ± .268  1.26 ± .246  1.45 ± .274  
BMI 26.8 ± 3.95  26.8 ± 3.63  26.6 ± 4.69  
CRP 3.57 ± 6.84  3.52 ± 7.17  3.79 ± 5.95  
eGFR 88.1 ± 17.0  89.4 ± 16.7  84.2 ± 17.3  
SBP 141 ± 20.7  141 ± 20.4  14.1% ± 21.4  
ApoA1: Apolipoprotein 1, BMI: body mass index, CRP: C-reactive protein, DM: Diabetes 
Mellitus, eGRF: estimated glomular filtration rate, SBP: systolic blood pressure.  
Data are presented by mean ± standard deviation for continuous variables, numbers (%) 
for categorical variables and median (inter quartile range) for biochemical parameters 
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4.2 Determinants of plasma retinol levels 
Table 4 describes the association between plasma retinol and anthropometric and 
biochemical parameters. Significant associations were observed between plasma retinol and 
age, body mass index, apolipoprotein A1, eGFR and systolic blood pressure.  
In addition, differences in plasma retinol were observed between gender (with males 
having higher values than females (∆ 0.06 ± 0.04 µmol/L)) and in smokers (with current 
smokers having lower concentrations than non-smokers (∆ 0.07 ± 0.03 µmol/L)), while a 
history of diabetes, statin use or level of physical activity had no significant effect.   
Table 4, Association between plasma retinol and anthropometrics and biochemical 
parameters in BECAC patients  
Parameters Relationship with retinol  
 Population (N=3842)  
 r P-value 
Age -.065 .000 
ApoA1 .164 .000 
BMI .068 .000 
CRP -.121 .000 
eGFR -.183 .000 
SBP .049 .004 
Correlation coefficients are Spearman. Text in bold where P <0.05. BMI: Body Mass Index, 
SBP: Systolic blood pressure, CRP: C-reactive protein, eGRF: estimated glomular filtration 
rate, ApoA1: serum apolipoprotein A1 
 
4.2.1 Plasma retinol and food intake 
Table 5 displays the correlation analysis between plasma retinol concentration and 
food groups documented through the FFQ.  Consumption of meat and milk both showed a 
modest positive correlation with plasma retinol concentration at r: .092 (P: .000) and r: .048 
(p: .036) respectively. 
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Table 5, Association between plasma retinol and food groups 
Parameters Relationship with plasma retinol  
 
r. P-value  
Meat .092 .000  
Fish -.012 .600  
Egg .035 .131  
Milk .048 .036  
Cheese -.015 .498  
Lean fish -.018 .422  
Oily fish .006 .789  
Processed fish -.016 .474  
Cod livera .028 .524  
Fish oila .026 .628  
Correlation coefficients are Spearman. Text in bold where P for trend <0.05 
aCorrelation between fish oil/cod liver oil and plasma retinol in supplement users 
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4.2.2 Differences of variables according to plasma retinol deciles 
Table 6 presents descriptive data for CVD risk factors at baseline according to retinol 
deciles. Differences between groups were assessed by ANOVA. Significant differences 
between plasma retinol deciles was observed for, age  Apolipoprotein A1,body mass index, 
C-reactive protein, Diabetes glomular filtration rate, and systolic blood pressure.  
Table 6, characteristics of patients according to plasma retinol deciles, middle, upper and 
lower deciles of plasma retinol concentration.  
Parameters 1st decile 
(N=395) 
Middle deciles 
(N=3081) 
10th decile 
(N=368) 
P-trend 
Retinol 1.90 ± .223 a  2.86 ± .421   4.34 ± .606    
DM 13.7%  11.0%  13.3%  .160 b  
Physical activity 72.9%  75.2%  74.2%  .594  
Smoking 31.4%  25.7%  20.7%  .003  
Statin 78.2%  81.2%  78.8%  .243  
Age 63.0 ± 10.7  61.6 ± 10.3  61.9 ± 9.87  .018   
ApoA1 1.23 ± .281  1.32 ± .261  1.40 ± .285  .000  
BMI 26.1 ± 4.15  26.8 ± 3.89  27.4 ± 4.18  .000  
CRP 7.51 ± 14.0  3.17 ± 5.46  2.83 ± 3.62  .000  
eGFR 93.2 ± 14.8  88.9 ± 15.5  75.8 ± 24.7  .000  
SBP 139 ± 21.9  141 ± 20.3  144 ± 21.6  .003  
ApoA1: Apolipoprotein A1, BMI: body mass index, CRP: C-reactive protein, DM: Diabetes 
Mellitus, GRF: glomular filtration rate, SBP: systolic blood pressure. Text in bold where P 
<0.05 
amean ± SD and  
b P values are ANOVA 
Data are presented by mean ± standard deviation for continuous variables, categorical 
data is presented as percentage of exposure 
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4.3 Survival analysis 
The average follow up for total mortality in the 3842 patients was 2659 days (7.3 
years, 95% confidence interval 2641-2677 days).  In total, 280 patients died during the follow 
up period (7.9%). Of these, 224 were males and 56 were females. Cardiovascular death 
occurred in 149 patients (121 males and 28 females) and non-cardiovascular causes of death 
were noted in 131 patients (103 males and 28 females).  
 Table 7 presents the distribution between patients who died and patients who were 
alive at the end of the study by deciles of plasma retinol concentrations. Notably, the 
number of events in certain subgroups the number of events are relatively low (< 30).  
The Kaplan-Meier analysis was used to evaluate the difference in survival between the 
deciles of retinol in our study. Figure number 6 through 8 and Table 7 provide evidence 
supporting the assumption that mortality is significantly different between exposure groups 
among total and male patients, but not among female patients. The mortality rates were 
highest among patients in the 10th decile and lowest in the middle deciles of plasma retinol. 
Female patients does not provide sufficient events for further mortality risk analysis. 
Table 7, Summary of events in population presented in a cross table of mortality, gender and 
plasma retinol deciles  
 
Parameters 
Total population 1st decile Middle deciles 10th deciles 
N Event % N Event % N Event %  N Event %  
All-Cause             
 
All 3842a 280b 7.86 395 37 9.37 3079 199 6.46 368 44 11.6 
Male 2784 224 8.05 261 25 9.60 2249 162 7.20 273 37 13.6 
Female 1059 56 5.29 134 12 9.00 830 37 4.46 95 7 7.45 
CVD             
 
All 3842 149 3.88 395 17 4.30 3079 108 3.51 368 24 6.52 
Male 2784 121 4.35 261 13 4.98 2249 88 3.91 273 20 7.33 
Female 1059 28 2.64 134 4 2.98 830 20 2.41 95 4 4.21 
NCVD             
 
All 3842 131 3.41 395 20 5.06 3079 91 2.96 368 20 5.43 
Male 2784 103 3.70 261 12 4.60 2249 74 3.29 273 17 6.23 
Female 1059 28 2.64 134 13 9.70 830 17 2.05 95 3 3.16 
CVD: cardiovascular death, NCVD: death of non-cardiovascular origin 
a N is given as number of days 
b Number of positive events 
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Figure 6, Survival function for all-cause mortality according to plasma retinol deciles 
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Figure 7, Survival function for CVD-related mortality according to plasma retinol deciles 
 
 
Figure 8, Survival function for non-CVD-related mortality according to plasma retinol deciles 
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4.4 Cox regression model 
4.4.1 Association with total mortality  
First, plasma retinol was used as a continuous variable. The crude model without any 
adjustments showed a risk increase for 1 µmol/L plasma retinol for total mortality of 1.30 
with a 95% confidence interval of 1.11, 1.52 (table 8). Adjustment for age and gender did not 
substantially change the hazard ratio (HR 1.33, 95% CI 1.14, 1.51). Further adjustment also 
did not change the association (model 3: HR 1.33, 95% CI 1.14, 1.51; model 4: HR 1.33, 95% 
CI 1.14, 1.51). 
When analyzing plasma retinol in quartiles, a significant association of plasma retinol 
quartiles with total mortality was no longer observed (HR for the 4th quartile, compared to 
the 1. Quartile was 1.20, 95% CI .87, 1.65). Further adjustment did not change the 
association substantially (data not shown). 
In addition, Cox regression was used to analyze total mortality-risk depending on 
plasma retinol deciles. When data for the total population were analyzed, all-cause mortality 
risk was found higher in the 1st (HR 1.38, 95% CI .97, 1.96) and 10th (HR 20.3, 95% CI 1.46, 
2.81) decile of retinol in the crude analysis (Model 1, Table 9). The HR was significant, 
however, only for plasma retinol levels in the upper decile, but not in the lowest decile. 
Adjustment for age and gender (model 2) did not change the association substantially. 
Further adjustments also did not change the association (model 3 and 4, table 9).   
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Table 8, Cox regression models for plasma retinol and all-cause mortality risk in patients of 
the BECAC study (n=3842) the Hazard ratio was calculated for 1µmol/l increase in plasma 
retinol. 
Predictor variable Hazard Ratio (HR) 95% CI for HR P-value 
Lower Upper 
Model 1 1.30 1.11 1.53 .001 
Model 2 1.33 1.14 1.51 .000 
Model 3 1.30 1.09 1.55 .003 
Model 4 1.33 1.12 1.59 .002 
ApoA1: apolipoprotein A1, BMI: body mass index, CRP: C-reactive protein, DM: diabetes 
mellitus, eGRF: estimated glomular filtration rate, SBP: systolic blood pressure, Text in bold 
where P <0.05 
a P values provided in the Middle deciles row are linear trend across decile groups 
b Hazard ratio represents change in mortality risk 
Model 1: crude model  
Model 2: adjusted for age (in years) and gender  
Model 3: further adjusted for CRP, eGFR and ApoA1  
Model 4: Further adjusted for DM, statin, physical activity, smoking, BMI, and SBP  
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Table 9, Cox regression models for plasma retinol deciles and all-cause mortality risk in 
patients of the BECAC study (n=3842) 
Predictor variable Hazard Ratio (HR) 95% CI for HR P-value 
Lower Upper 
Model 1     
 Middle deciles[referent]    .000a 
 1st decile 1.38b .97 1.96 .072 
 10th decile 2.03 1.46 2.81 .000 
Model 2     
 Middle deciles[referent]    .000 
 1st decile 1.27 .89 1.80 .189 
 10th decile 2.06 1.49 2.59 .000 
Model 3     
 Middle deciles[referent]    .006 
 1st decile 1.11 .76 1.61 .591 
 10th decile 1.80 1.25 2.60 .001 
Model 4     
 Middle deciles[referent]    .003 
 1st decile 1.05 .72 1.53 .802 
 10th decile 1.84 1.27 2.65 .001 
ApoA1: apolipoprotein A1, BMI: body mass index, CRP: C-rective protein, DM: diabetes 
mellitus, eGRF: estimated glomular filtration rate, SBP: systolic blood pressure, Text in bold 
where P <0.05 
a P values provided in the Middle deciles row are linear trend across decile groups 
b Hazard ratio represents change in mortality risk 
Model 1: crude model  
Model 2: adjusted for age (in years) and gender  
Model 3: further adjusted for CRP, eGFR and ApoA1  
Model 4: Further adjusted for DM, statin, physical activity, smoking, BMI, and SBP  
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4.4.2 Association with cardiovascular disease related mortality 
First, plasma retinol was used as a continuous variable. The crude model without any 
adjustments showed a risk increase for 1 µmol/L plasma retinol for CVD-related mortality of 
1.39 with a 95% confidence interval of 1.12, 1.71 (table 10). Adjustment for age and gender 
did not substantially change the hazard ratio (HR 1.39, 95% CI 1.15, 1.71). Further 
adjustment also did not change the association, but significance was lost when adjusted for 
model 3 and 4 (model 3: HR 1.18, 95% CI .34, 1.49; model 4: HR 1.22, 95% CI .97, 1.54). 
When analyzing plasma retinol in quartiles, a significant association of plasma retinol 
quartiles with total mortality was no longer observed (HR for the 4th quartile, compared to 
the 1. Quartile was 1.39, 95% CI .89, 2.18). Further adjustment did not change the 
association substantially (data not shown). 
Cox-regression was also used to analyze CVD-related mortality-risk depending on 
plasma retinol deciles. When the data for the total population were analyzed, CVD-related 
mortality risk was found higher in the 1st (HR 1.17, 95% CI .70, 1.95) and 10th (HR 2.01, 95% 
CI 1.30, 3.16) decile of plasma retinol in the crude analysis (Model 1, Table 11). The HR was 
significant, however, only for plasma retinol levels in the upper decile, but not in the lowest 
decile. Adjustment for age and gender (model 2, table 11) did not change the association 
substantially. After further adjustments significance was lost, HR remained increased for 
patients in the 10th decile, however, HR indicated decreased risk, although of no significance 
among patients in the 1st decile (model 3 and 4, table 11).   
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Table 10, Cox regression models for plasma retinol and CVD-related mortality risk in 
patients of the BECAC study (n=3842) the Hazard ratio was calculated for 1µmol/l increase 
in plasma retinol. 
Predictor variable Hazard Ratio (HR) 95% CI for HR P-value 
Lower Upper 
Model 1 1.39 1.12 1.71 .004 
Model 2 1.39 1.15 1.70 .001 
Model 3 1.18 .34 1.49 .162 
Model 4 1.22 .97 1.54 .096 
ApoA1: apolipoprotein A1, BMI: body mass index, CRP: C-reactive protein, DM: diabetes 
mellitus, eGRF: estimated glomular filtration rate, SBP: systolic blood pressure, Text in bold 
where P <0.05 
a P values provided in the Middle deciles row are linear trend across decile groups 
b Hazard ratio represents change in mortality risk 
Model 1: crude model  
Model 2: adjusted for age (in years) and gender  
Model 3: further adjusted for CRP, eGFR and ApoA1  
Model 4: Further adjusted for DM, statin, physical activity, smoking, BMI, and SBP  
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Table 11, Cox regression models for plasma retinol deciles and cardiovascular mortality risk 
in patients of the BECAC study (n=3842) 
Predictor variable Hazard rate 95% CI for HR P-value 
Lower Upper 
Model 1     
 Middle deciles [referent]    .007 
 1st decile 1.17 .70 1.95 .546 
 10th decile 2.03 1.30 3.16 .002 
Model 2     
 Middle deciles [referent]    .006 
 1st decile 1.07 .64 1.78 .809 
 10th decile 2.06 1.32 3.21 .001 
Model 3     
 Middle deciles [referent]    .414 
 1st decile .97 .56 1.68 .912 
 10th decile 1.41 .85 2.34 .188 
Model 4     
 Middle deciles [referent]    .359 
 1st decile .89 .52 1.56 .692 
 10th decile 1.43 .85 2.40 .173 
ApoA1: apolipoprotein A1, BMI: body mass index, CRP: C-rective protein, DM: diabetes 
mellitus, eGRF: estimated glomular filtration rate, SBP: systolic blood pressure, Text in bold 
where P <0.05 
a P values provided in the Middle deciles row are linear trend across decile groups 
b Hazard ratio represents change in mortality risk 
Model 1: crude model  
Model 2: adjusted for age (in years) and gender  
Model 3: further adjusted for CRP, eGFR and ApoA1  
Model 4: Further adjusted for DM, statin, physical activity, smoking, BMI, and SBP 
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4.4.3 Association with non-cardiovascular disease related mortality 
First, plasma retinol was used as a continuous variable. The crude model without any 
adjustments showed a risk increase for 1 µmol/L plasma retinol for non-CVD-related 
mortality of 1.21, however, the increase was not found significant with a 95% confidence 
interval of .95, 1.54 (table 12). Adjustment for age and gender did not substantially change 
the hazard ratio (HR 1.24, 95% CI .98, 1.56). Further adjustment also did not change the 
association, but the adjustments resulted in a gain of significance for model 3 and 4 (model 
3: HR 1.44, 95% CI 1.10, 1.88; model 4: HR 1.46, 95% CI 1.12, 1.91). 
When analyzing plasma retinol in quartiles, a significant association of plasma retinol 
quartiles with total mortality was no longer observed (HR for the 4th quartile, compared to 
the 1. Quartile was 1.02, 95% CI .64, 1.62). Further adjustment did not change the 
association substantially (data not shown). 
Lastly, Cox regression was used to analyze non-CVD-related mortality-risk depending 
on plasma retinol deciles. When the data for the total population were analyzed, non-CVD-
related mortality risk was found higher in the 1st (HR 1.63, 95% CI 1.00, 2.64) and 10th (HR 
2.21, 95% CI 1.25, 3.29) decile of retinol in the crude analysis (Model 1, Table 13). The HR 
was significant in both the lower and upper decile in the crude analysis. Adjustment for age 
and gender (model 2, table 13) did not change the association substantially, however, the 
association only remained significant for plasma retinol levels in the upper decile (HR 2.06, 
95% CI 1.27, 3.34), but not in the lowest decile (HR 1.51, 95% CI 0.93, 2.45). Further 
adjustments did not change the association substantially (model 3 and 4, table 13). 
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Table 12, Cox regression models for plasma retinol and non-CVD-related mortality risk in 
patients of the BECAC study (n=3842) the Hazard ratio was calculated for 1µmol/l increase 
in plasma retinol. 
Predictor variable Hazard Ratio (HR) 95% CI for HR P-value 
Lower Upper 
Model 1 1.21 .950 1.54 .122 
Model 2 1.24 .984 1.56 .069 
Model 3 1.44 1.10 1.88 .008 
Model 4 1.46 1.12 1.91 .006 
ApoA1: apolipoprotein A1, BMI: body mass index, CRP: C-reactive protein, DM: diabetes 
mellitus, eGRF: estimated glomular filtration rate, SBP: systolic blood pressure, Text in bold 
where P <0.05 
a P values provided in the Middle deciles row are linear trend across decile groups 
b Hazard ratio represents change in mortality risk 
Model 1: crude model  
Model 2: adjusted for age (in years) and gender  
Model 3: further adjusted for CRP, eGFR and ApoA1  
Model 4: Further adjusted for DM, statin, physical activity, smoking, BMI, and SBP  
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Table 13, Cox regression models for plasma retinol deciles and non-cardiovascular mortality 
risk in patients of the BECAC study (n=3842) 
Predictor variable Hazard Ratio (HR) 95% CI for HR P-value 
Lower Upper 
Model 1     
 Middle deciles [referent]    .006 
 1st decile 1.63 1.00 2.64 .049 
 10th decile 2.21 1.25 3.29 .004 
Model 2     
 Middle deciles [referent]    .007 
 1st decile 1.51 .93 2.45 .096 
 10th decile 2.06 1.27 3.34 .003 
Model 3     
 Middle deciles [referent]    .005 
 1st decile 1.25 .75 2.09 .401 
 10th decile 2.33 1.38 3.94 .001 
Model 4     
 Middle deciles [referent]    .005 
 1st decile 1.21 .72 2.03 .476 
 10th decile 2.38 1.41 4.03 .001 
ApoA1: apolipoprotein A1, BMI: body mass index, CRP: C-rective protein, DM: diabetes 
mellitus, eGRF: estimated glomular filtration rate, SBP: systolic blood pressure, Text in bold 
where P <0.05 
a P values provided in the Middle deciles row are linear trend across decile groups 
b Hazard ratio represents change in mortality risk 
Model 1: crude model  
Model 2: adjusted for age (in years) and gender  
Model 3: further adjusted for CRP, eGFR and ApoA1  
Model 4: Further adjusted for DM, statin, physical activity, smoking, BMI, and SBP 
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5 Discussion 
The discussion section of this paper will focus on explaining the results of our study, 
with emphasis on comparing our results with the hypothesis and previous studies. In 
addition, the quality of the study and its model will also be discussed.  
5.1 Results 
In this study, we evaluated the risk of all-cause, CVD-related and non-CVD-related 
mortality depending on plasma retinol concentration in a population with established CVD. 
The main finding of this analysis was that high levels of plasma retinol in patients with 
coronary heart disease let to a higher risk of total and non-CVD mortality than in patients 
with plasma retinol levels in the ‘middle range’. High plasma retinol levels were also 
associated with increased risk of CVD-mortality, however, this was no longer significant after 
adjustment. Patients with low plasma retinol also had a higher mortality risk, but the 
assumption did not achieve significance.  
5.2 Result discussion 
5.2.1 Differences in mortality 
The survival plots suggested that mortality risk was greatest among patients with 
elevated plasma retinol, and lowest in the referent levels. The survival analysis supports the 
assumption that patients with plasma retinol concentration between 2.15 and 3.81 µmol/L 
have a lower all-cause mortality rate compared to patients with either < 2.15 µmol/L or 
>3.81 µmol/L.  
During the on average 2659 days (7 years and 3 months) of follow-up 7.9 percent of 
the patients died, of which slightly more were CVD-related compared to non-CVD-related. 
The number of events allowed the study to show significant association in several models. It 
also allowed for investigation of the extreme ends to the plasma retinol specter. The original 
plan was to split the population by gender (matching) and evaluate them separately in 
addition to the total population analysis to account for differences between sexes. Matching 
for gender was, however, deemed unsuitable, as numbers of events among women were 
low and gender was added to adjustment models. 
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We observed a U-shaped association between plasma retinol and mortality. Patients 
in the higher and lower deciles having higher mortality than the middle deciles referent 
creating the U-shape, expect for CVD-related mortality after adjustment. The trend is 
illustrated in figure 9 and 10, which illustrate in unadjusted and adjusted HRs respectively.  
Figure 9, HR for all-cause, CVD, and non-CVD-related mortality, HRs are unadjusted 
 
Figure 10, HR for all-cause, CVD, and non-CVD-related mortality, HR are adjusted for variables in Cox regression model 4 
 
 
5.2.2 Plasma retinol levels and total mortality 
 The mortality risk analysis revealed that HR increased by 30% per 1 µmol/L plasma 
retinol and that confounders had little effect on the association. Contradictory, no 
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association was found when plasma retinol was evaluated in quartiles as done in previous 
studies. Extreme values of plasma retinol was evaluated to test the hypothesis that upper 
and lower exposure groups of quartiles included homeostatically controlled plasma retinol 
levels. The results of the mortality risk analysis for plasma retinol deciles indicated a 38% 
increased mortality risk for patients in the lowest decile and 106% increased mortality risk 
for patients in the highest decile, also after adjustments.  
5.2.3 Plasma retinol levels and CVD-related mortality 
Contradictory to the significance seen in total mortality HR models, increased CVD-
related mortality risk was only found significant in the highest decile of plasma retinol before 
adjustment. The assumptions of increased risk for patients in the highest decile was 
sustained as the hazard risk stays elevated, however, the hazard risk changes after further 
adjustments. Among patients in the lower decile of plasma retinol an increase in hazard rate 
was first indicated, but a lower hazard rate was indicated after adjustmen, the assoisation 
were never of significance. 
5.2.3.1 Low plasma retinol concentrations and CVD mortality 
The Kaplan-Meier analysis deemed mortality risk for patients with plasma retinol 
concentration in the lowest decile of distribution to be higher than the middle decile 
referent and lower than for patients in 10th decile of plasma retinol. Three previous studies 
have suggested that low plasma retinol concentrations may increase the risk of CVD-related 
mortality [7, 43, 44]. However, the same results were not seen in the mortality risk analysis. 
In contrast to previous findings which showed increased risk in participants with 
concentrations < 2.90 µmol/L, no association of increased or decreased risk in BECAC 
patients with plasma retinol concentration < 2.15 µmol/L could be made.  
5.2.4 Elevated plasma retinol concentration and CVD mortality 
BECAC patients with plasma retinol concentration > 3.81 µmol/L were associated with 
significantly higher mortality risk than patients with < 3.81 µmol/L. After further adjustment 
for confounders, the mortality risk was 40% higher in patients with elevated plasma retinol 
concentration, but the difference was no longer significant.  
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5.2.5 Comparison with previous studies 
The models of our study indicated similar assumptions for total mortality and CVD-related 
mortality. The U-shaped hazard risk distribution is present in previous studies and the 
current. Although there seems to be a clear trend there are differences in significance of 
results, size of change and if the highest hazard risk is found at the lower or higher end of 
the range. Our study stood as CVD-related mortality risk no longer was significant after 
adjustments and that no assumptions of change for CVD-related mortality risk could be 
made for patients with low plasma retinol.  
5.2.6 Food intake and plasma retinol concentration 
Comparing food intake to plasma retinol concentrations provided significant 
correlations between two out of ten food groups and plasma retinol. Milk and meat had 
modest positive correlation with plasma retinol. This supports former evidence that plasma 
retinol stays unafected by food intake in people with subclinical vitamin A stores [25].   
5.3 Method evaluation 
In this study, we evaluated the patient’s risk of CVD based on the Vitamin A status. 
The patients were all part of a CVD diagnosis study and some were part of a randomized 
controlled trail evaluating vitamin B supplementation and CVD risk. The methods utilized in 
this study and its population will now be further discussed. 
5.3.1 Baseline data 
The majority of data variables were recorded through robust methods such as blood 
sampling, and assessment by trained physicians and nurses, or from self-administered 
questionnaires verified by medical history [42]. The data were originally collected for CVD 
diagnosis trial and a vitamin B intervention study and thus, some additional data might have 
been beneficial. Plasma concentrations of other vitamin A metabolites and data on dietary 
intake of food sources rich in vitamin A could have increased understanding of the 
population’s vitamin A status [42, 49].   
In contrast to the more robust data, some data were self-reported. Self-reported 
smoking habits were combined with cotinine values to make the estimate of exposure more 
robust, as proposed by Svingen et al. [42], patients’ smoking history was not accounted for. 
The physical activity data was also self-reported as patients were asked to classify 
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themselves as being active twice a week or not. The data of self-reported physical activity 
have several limitations. Firstly, patients had to estimate their average physical activity and 
remember how active they had been the preceding year. Secondly, self-reported physical 
activity tends to overestimate actual physical activity [55]. Thirdly and lastly, the validity of 
the activity data is limited by the fact that the cut-off of physical activity twice a week does 
not reflect the recommendations from the Norwegian Directory of Health, which 
recommends 20 minutes of activity a day or 150 minutes a week [56].  
Additionally, because the significant increased HR of non-CVD-related mortality was 
indicated in exposure groups of plasma retinol, further data on mortality causes would have 
been of interest. No such data was available as endpoints were classified as either CVD-
related or not CVD-related. 
5.3.2 Plasma retinol as a biomarker 
The accuracy and repeatability of plasma retinol measuring have been validated and 
thoroughly discussed in the report by Midttun et al. [35]. While the measurement of plasma 
retinol is deemed accurate and reliably tested in large studies from small amounts of plasma, 
questions have been asked regarding its power as a biomoarker [15, 35].  
The regulation of plasma retinol by the liver and the lack of predictability of the 
homogenically controlled plasma retinol plateau compromise its effectiveness as a 
biomarker [17]. Being able to predict cut-off points where plasma retinol no longer is 
homogenically controlled, could have increased the strength of our assumptions by ensuring 
that estimations were made on the actual population of participants with subclinical vitamin 
A deficiency or toxicity. Further, such values would have allowed us to maximize the amount 
of patients in the exposure groups to gain statistical power. The BOND report by Raiten et 
al., suggest a need for a separate, complementary biomarker of vitamin A, to account for the 
homogenically controlled range and as plasma retinol is not found effective in estimating of 
vitamin A intake or to monitor effects of dietary interventions and food based strategies 
[25].  
A separate problem with plasma retinol as a biomarker is the influence of inflammation 
and infection. The isolated influence of acute response proteins on plasma retinol in contrast 
to total body vitamin A is well documented, but the strength and rate of alteration is not 
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clearly standardized. An effect was found but not proven by Duncan et al. [38], thus a clear 
standardized approach for adjustment is yet to be established.  
5.3.3 Plasma retinol groups 
The process of creating the plasma retinol groups for mortality risk estimation provided a 
conflict of interest. Our first approach was to mimic previous studies by dividing plasma 
retinol concentration into quartiles. The quartiles were elected to optimize the 
transferability of our results to the previous studies. As quartiles did not represent trend 
seen in the mortality risk analysis of continuous plasma retinol data, more extreme 
groupings where discussed. Two areas of focus were considered when electing the new 
exposure groups. Firstly, to get sufficient number of patients i.e. events in the exposure 
groups, and secondly, to avoid including patients with homogenically controlled plasma 
retinol concentrations. As a result, plasma deciles were elected for the project. This 
somewhat cautious approach in terms of homogenically controlled range was possible as our 
population and number of outcomes were large. Even though focus was on having sufficient 
events in the exposure group and a large population size, the prevalence of events was 
relatively low, especially when the population was split by gender. A better understanding of 
changes in serum retinol concentration first explained by Olsen et al. (figure 3) could have 
improved the number of patients and outcomes in the exposure groups [17]. 
5.3.4 Dietary intake – FFQ 
The advantages of utilizing a FFQ to report dietary intake is that they are cost effective, 
simple to use, and show higher compliance among participants compared to other methods 
[51]. Limitations are present as the method is strictly retrospective. Additionally, the method 
may produce a one-dimensional picture of the participant’s food intake and it is relying on 
the  participants’ ability to remember what their food intake was like the last year. 
Underreporting food intake is also a common problem especially among women [57]. The 
FFQ used is validated, widely used, and is made to fit Norwegian food and meal patterns 
[51]. However, the FFQ used was developed to investigate eicosapentaenoic acid (EPA) and 
docosahexaeonic acid (DHA) fatty acid consumption and did not provide data on vitamin A 
rich food sources. Data on food groups such as liver, dairy products, dark colored fruits and 
vegetables as well as vitamin A and β-carotene supplementation was not present in available 
data set.  
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5.3.5 Statistical analysis 
LDL cholesterol data and other cholesterol related parameters were left out of the 
regression model due to the extensive use of cholesterol lowering statin treatment (80% of 
population). In regards to the hypothesis of this study, electing the middle deciles as the 
referent for the Cox regression analysis was determined the best fit and provided evidence 
to the assumption of a U-shaped hazard rate distribution. The tested more than one  of 
exposure and our data decision to use several clasifications  
5.4 Population 
There were several benefits of utilizing the WENBIT population for this study. The 
data-set was easily retrieved from the Department of heart disease at HUS at no cost and 
without taxing the participants any further as the data already existed.  
Performing this study on patients with established CVD poses both benefits and 
disadvantages. There are several reason why the BECAC population was elected for WENBIT 
and this study. As the patients had already established CVD, they have an increased risk of 
new events (exposure). The increased likelihood of events allows the investigator to expect 
significant results in smaller number of study participants, as opposed to what could be 
expected when doing the same study with participants from a healthy population. Thus, 
reducing the amount of resources needed to perform the study, in form of cost, labor, and 
stress on population.   
5.5 Limitations 
Strength of introductory information may be questioned as information was primarily 
gained through reviews and other secondary sources, although, some primary sources 
where used.  
5.5.1 Internal validity  
The study design renders assumption of causation invalid. Assumptions of association 
can be made but structural limitations must be accounted for. Assumptions are limited by 
low number of events in exposure groups, lack of significance in some models and by 
alterations assumptions or significance produced by adjusting for confounders. Additionally, 
we tested multiple hypothesis. Therefore, results must be interpreted with caution.   
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We do know that the B vitamin intervention given to patients in WENBIT did not 
affect; mortality, risk of CVD or alter biomarkers of CVD such as IL-6 and CRP [50]. However, 
we do not have information on whether B-vitamin supplementation will affect plasma 
retinol concentrations, but we do not have any knowledge on that it does so. 
5.5.2 External validity 
The cut-off values of the decile groups have little external validity, as they are specific 
for this study and are not assumed to represent any previously discussed cut-off values for 
either toxicity or deficiency. The disadvantages of having a population that is predisposed for 
outcomes cannot be assumed to fully represent the normal population. 53% of deaths 
where CVD-related in the study. Which is substantially higher than 30% seen in the general 
population of Norway [6]. The increased prevalence of CVD is assumed to originate from the 
patients under study’s increased risk through previous exposure. The factors increasing rates 
of CVD in the study population may alos have caused exposure and confounding variables to 
respond differently in the population under study, in relation to how it is expected to react 
in healthy individuals, reducing validity.   
5.5.3 Confounding 
The Cox regression model was used to adjust for vascular risk factor exposure, but some 
potential for unmeasured and residual confounding remains. For example, we did not adjust 
for dietary vitamin A intake, supplement use or disease history. Gender was added to the 
model after matching by gender was discarded due to lack of events in exposure groups 
when divided by gender.  
Confounders proved to play a role in for some regression models, as significance was lost 
or in some test insignificant mortality risks changed from increase to decrease when 
adjusting for model 2 or model 3. As with any observational study, residual confounding by 
socioeconomic status, lifestyle variables, and other factors cannot be excluded.  
The correlation analysis revealed as expected that CRP was negatively associated with 
plasma retinol levels. Its established that increased CRP concentrations in plasma reduce 
plasma retinol without affecting total body vitamin A. The levels of CRP was significantly 
higher in the 1st decile of plasma retinol at 7.51 mg/L (± 14.0 mg/L), which is twice the mean 
value of the Middle deciles referent and 10th decile (3.17 ± 5.46 mg/L and 2.83 ± 3.62, 
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respectively). The significant higher mean CRP in the 1st decile of plasma retinol may suggest 
that some of the patients of the 1st decile group may have been false positives. 
5.6 Conclusion and suggestions for future work 
There are several limitations to our assumptions. However, they the follow the same U-
shaped trend indicated by Goyal et al. suggesting that the mortality risk is greater in 
populations with low or elevated plasma retinol [44]. The assumptions also indicated that 
low or high plasma retinol levels does not predict CVD-related mortality singularly but rather 
predicts increased all-cause mortality. The accumulation of the increase in HR seen for 
continuous plasma retinol, the U-shaped HR, and the HR scores throughout the models 
suggest that mortality risk were higher among patients with elevated plasma retinol 
concentration.  
Several studies have indicated that vitamin A metabolites may have important roles in 
preventing atherosclerotic CVD development and that vitamin A metabolites may be 
efficiently affected by supplementation. However, recent randomized supplementation 
studies have failed to show health benefits from taking vitamin A supplements [47, 48]. The 
assumptions also indicated increased mortality risk among patients with low vitamin A 
status, suggesting that sub-groups might benefit from diet intervention or supplementation.  
A better understanding of plasma retinol as a biomarker of vitamin A status is needed. 
Especially when it comes to understanding the relation between vitamin A liver stores, 
inflammation, and serum retinol. Further investigation of the increased risk seen at the 
extreme ends of plasma retinol concentration is needed to further support or disprove the 
assumption and circle in cut-off values for change in mortality risk. The ideal approach to 
investigating Vitamin A and mortality, would be in a randomized intervention study where 
supplementation were adjusted for serum retinol and markers of inflammation. 
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